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R E S U M E  
INTRODUCTION 
Les progrès dans le diagnostic et le traitement du cancer chez l'enfant, 
l'adolescent et l'adulte ont fortement augmenté l'espérance de vie des femmes 
pré-ménopausées atteintes de cancer. En conséquence, il existe une population 
croissante de survivants adolescents et adultes qui ont eu un cancer dans 
l'enfance. Pour la majorité des femmes les dommages ovariens causés par la 
radiothérapie ou la chimiothérapie peuvent provoquer une ménopause précoce. 
La cryopréservation des ovaires est un des moyens pour la préservation à long 
terme des cellules germinales de la femme. Avec cette méthode, les ovocytes en 
prophase I contenus dans les follicules primordiaux sont préservés. Ceci pourrait 
constituer une alternative attrayante car la différenciation cytoplasmique n’est pas 
complète dans les ovocytes immatures. Les noyaux sont bloqués au stade de la 
vésicule germinale. Il existe un nombre élevé d’ovocytes immatures dans le cortex 
ovarien, de sorte que la méthode peut être également utilisée pour des filles pré-
pubères. Avec cette méthode, les ovocytes immatures peuvent être préservés en 
même temps que d’autres cellules ovariennes nécessaires au développement et à 
la maturation des ovocytes. Cette technique permettrait non seulement la 
préservation, de gamètes femelles à divers stades de développement, ainsi que 
celle des fonctions endocriniennes de l’ovaire. Notre étude vise à évaluer la 
vitrification comme méthode de cryopréservation des tissus ovariens, et évaluer 
l’utérus comme site de transplantation des tissus ovariens congelés-décongelés. 
METHODOLOGIE 
Des souris femelles OF1, et âgées de douze et vingt semaines ont été utilisées 
pour cette étude. Dans le groupe de vitrification, la technique opératoire a été 
réalisée en deux temps. Dans le premier temps, l’ovaire gauche a été extrait pour 
être cryopréservé, le pédicule ovarien gauche a été ligaturé avec du vicryl 4/0 pour 
assurer l’hémostase, le péritoine a été fermé par une suture continue et la peau a 
été fermée par des points séparés en utilisant soit du nylon 6/0 ou du vicryl 4/0. 
Deux semaines plus tard, une seconde laparotomie a été effectuée pour extraire 
l’ovaire droit et pour transplanter des biopsies de l’ovaire gauche congelées-
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décongelées dans la partie la plus distale de la corne utérine gauche. Dans le 
groupe de contrôle, la technique opératoire a été effectuée en un seul temps 
opératoire. Par laparotomie, les deux ovaires ont été extraits et les pédicules 
ovariens ont été ligaturés avec du vicryl 4/0. Les ovaires ont ensuite été lavés 
dans une solution HB1, et immédiatement transplantés dans la partie la plus 
distale de la corne utérine gauche. 
La solution mère de vitrification (VS 100%) est préparée en ajoutant 20.5% [V/V] 
de diméthyl sulphoxide [DMSO], 15.5% [W/V] d’acétamide, 10.0% [V/V] de 
propylène glycol et 6.0% [W/V] de polyéthylène glycol 6000, à une solution HB1. 
La dilution de la solution mère de VS (100%) avec la solution de HB1 permet la 
formation de concentrations de 12.5%, 25%, et 50% de VS. Les ovaires collectés 
ont été coupés en 2 à 4 pièces à l’aide d’un scalpel stérile, lavées dans une 
solution de HB1, puis immergées successivement à température ambiante dans 
des solutions VS, 12.5%, 25% (15 minutes/solution), puis en chambre froide (4°C) 
dans les solutions VS 50% et 100% (15 minutes/solution). Enfin, chaque fragment 
ovarien a été placé dans une ampoule de congélation avec 0.5mL de VS à 100%, 
puis transféré en stockage dans l’azote liquide (-196°C) jusqu’à utilisation. Les 
fragments ovariens ont été décongelés en immergeant les ampoules pendant 
quelques secondes dans de l’eau à 37°C. Les cryoprotecteurs sont éliminés par 
dilution successive dans des bains de VS 50%, 25% et 12,5% (10 min./bain, 
température ambiante). Les fragments ovariens sont finalement lavés dans une 
solution HB1. 
La viabilité des tissus ovariens (tests) congelés-décongelés et celle des fragments 
ovariens des groupes contrôle, n’ayant pas subit la cryoconservation, a été 
évaluée par analyse histologique avant et après la transplantation. La 
fonctionnalité des biopsies ovariennes transplantées a été évaluée par comptage 
des grossesses. 
RESULTATS 
L’analyse histologique a montré qu’il y avait une différence entre le nombre de 
follicules normaux dans les biopsies fraîches et vitrifiées-décongelées. Au moyen 
du test-t, la différence se révèle statistiquement significative par rapport en 
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considérant tous les types de follicules. Cependant que la différence entre le 
nombre de follicules normaux dans des greffes ovariennes fraîches et vitrifiées-
décongelées au moyen du test-t, se révèle non statistiquement significative 
(Valeur de P = 0.6). 
Les résultats en terme de grossesse chez les souris après la transplantation des 
greffes fraîches ont été 7 souriceaux viables puis fertiles et 1 mort néonatale. Les 
résultats chez les souris après la transplantation des greffes congelés-décongelés 
ont été 2 morts in utero et l’analyse histologique posthume se révèle hypoplasies 
pulmonaires bilatérales, et 2 morts néonatales et l’analyse histologique posthume 
se révèle rien. 
CONCLUSIONS 
L’ovaire peut tolérer une exposition à la déshydratation osmotique et à la 
vitrification dans une solution concentrée de cryoprotecteurs.  
La technique de vitrification atteint les follicules à tous les stades de 
développement mais dans une moindre mesure les follicules primordiaux. 
L’utérus murin semble être un site de greffe adéquat pour la transplantation de 
tissus ovariens et peut conduire à des grossesses naturelles. 
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I N T R O D U C T I O N  
In recent years, fertility preservation has been evolving rapidly as a result of 
clinical imperatives and advances in technology (Gosden and Nango, 2002). 
Advances in diagnosis and treatment of childhood, adolescent and adult cancer 
have greatly enhanced the life expectancy of premenopausal women with cancer. 
As a result, there is growing population of adolescent and adult long-term 
survivors of childhood cancer and for the majority of women, ovarian damage 
caused by radiotherapy or chemotherapy would result in premature menopause 
(Donnez et al., 2000). When the deleterious effects of the treatment are not 
reversible, mature oocytes, embryo cryopreservation and ovarian tissue 
cryopreservation may be considered to restore fertility following the completion of 
the treatment. Mature oocytes cannot be cryopreserved easily, this is because the 
cytoplasm volume and water content is much higher than in other cells, and the 
nucleus is blocked in metaphase II of meiosis which makes the spindle very fragile 
and sensitive to temperature and osmotic stress. Also, the collection of mature 
oocytes requires ovarian stimulation, which is not always possible because the 
high levels of estrogens induced may be deleterious in some cancers. 
Furthermore, this procedure should only be used in adult patients. Embryo 
cryopreservation is an established clinical technique that results in acceptable 
pregnancy rates, depending on the age of the patient. However, the patient must 
have a partner or be in a stable relationship at the time of the treatment and again 
women with estrogen-sensitive cancers cannot undergo the necessary ovarian 
stimulation before the in vitro fertilization (IVF) (Poirot et al., 2002). 
Cryopreservation of the ovaries (OTCP) is one of the means for long-term 
preservation of female germ cells (Donnez et al., 2000). In this method, prophase I 
oocytes contained in primordial follicles are preserved. This could be an attractive 
alternative because cytoplasmic differentiation is not complete in immature 
oocytes, nuclei are blocked in the germinal vesicle stage, and, there are large 
numbers of immature oocytes in the ovarian cortex. So, this method can be used 
as well for prepubertal patients as adult patients (Poirot et al., 2002). With this 
method, immature oocytes together with other ovarian cells necessary for 
development and maturation of oocytes can be preserved. This technique would 
enable not only the preservation of female gametes in diverse stages of 
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development but would also preserve the endocrine functions of the ovary 
(Sugimoto et al., 2000). Thus, the cryopreservation of ovarian tissue is a potential 
alternative or addition to the cryopreservation of embryos or mature oocytes for 
women at risk of premature ovarian failure (Poirot et al., 2002). 
The recent surge in ovarian tissue banking reflects the importance and the need of 
fertility conservation for many women facing premature ovarian failure, particularly 
those with cancer (Kim et al., 2001). After the success of animal experiments, 
reports have been published about ovarian tissue cryopreservation for such 
patients (Law, 1996). Most previous studies on cryopreservation employed slow 
freezing rapid thawing technique (Gosden et al., 1994). It is a time consuming 
procedure, and it requires special equipment such as a programmable freezer. 
Vitrification is an alternative cryopreservation method that might be effective for 
organ cryopreservation as well as for cryopreserving embryos and small 
specimens. Several kinds of cells including oocytes have been successfully 
cryopreserved by vitrification and, in some cases; the results were comparable or 
superior to slow freezing rapid thawing technique (Dinnys et al., 1995). The 
majority of grafts have been to the kidney, since it has a good blood supply and 
high concentration of angiogenic growth factors, but the uterus has a high blood 
supply and is also immunoprivileged. Transplantation procedures would be 
enhanced if the ovarian tissue could be successfully cryopreserved and 
transplanted into the uterus. Beer et al., 1999 found that intrauterine skin 
homograft survive in the uterus of the rat for the period of pregnancy. Kagabu and 
Umezu transplanted vitrified-thawed rat ovaries in the uterus and demonstrated 
that it was immunologically acceptable to the uterus (Kagabu and Umezu, 2000). 
However, none of the previous studies tried to test the fecundability of the 
cryopreserved and transplanted ovarian grafts in the uterus. In the present study 
we aimed to evaluate ultra-rapid freezing technique (vitrification technique) as a 
method of ovarian tissue cryopreservation, and to evaluate the uterine cavity as a 
site of ovarian tissue transplantation. 
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L I T E R A T U R E  R E V I E W  
1. Fertility preservation 
As survival rates for young cancer patients continue to improve, protection against 
iatrogenic infertility caused by chemotherapy with or without radiotherapy assumes 
higher priority. Hodgkin's disease is the most common malignancy in the 
population aged 15–24 years. Prolonged survival of almost 90% of patients is now 
expected for young patients treated with cytotoxic chemotherapy for Hodgkin’s 
disease. This is due to the introduction of effective chemotherapy such as MOPP 
(mechlorethamine, vincristine, prednisone and procarbazine) and/or ABVD 
(adriamycin, bleomycin, vinblastine and decarbazine) and its variants. Similar 
rates of long-term survival have been reported for patients with non-Hodgkin 
lymphoma, as well as for patients with other types of tumours receiving 
chemotherapy (Blumenfeld et al., 1999). It was estimated that by the year 2010 
one in 250 of the young adult population would be a long-term survivor of 
childhood cancer (Wallace, 1997). Moreover, cytotoxic agents have been also 
used as chemotherapy for various autoimmune diseases such as systemic lupus 
erythematosus (SLE), rheumatoid arthritis, and for the prevention of organ 
transplant rejection (Blumenfeld et al., 1999). 
Females are generally less susceptible than males to the deleterious effects of 
chemotherapy on the gonad. Nevertheless, ovarian dysfunction is well-recognized 
following combination chemotherapy. Treatment of Hodgkin's disease with 
mechlorethamine, vinblastine, procarbazine and prednisolone (MVPP), or MOPP 
results in ovarian failure in 19-63%. Amenorrhoea is much more commonly 
encountered in women over 30 years than in younger women where ovarian 
function appears to be preserved in 48-100% (Mackie et al., 1996). Long-term 
follow-up will be necessary as a number of these young women may subsequently 
progress to a premature menopause (Thomson et al., 2002). 
The major challenge faced by pediatric oncologists today is to sustain the 
excellent survival rates while striving to achieve optimal quality of life. One of the 
most frequently encountered and psychologically traumatic late complications of 
radiotherapy and chemotherapy for childhood cancer is infertility. Consequently, 
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attention is focusing on developing techniques to preserve the patient’s fertility 
(Chen et al., 1996) 
Advances in assisted reproduction and increasing interest in gamete extraction 
and maturation have focused attention on preserving gonadal tissue from children 
before commencement of sterilizing chemotherapy or radiotherapy, with the 
realistic expectation that future technologies will be able to utilize their immature 
gametes. The options available are dependent upon the sexual maturation of the 
patient. A number of strategies for protecting the ovaries and preserving fertility 
during cancer therapy have been attempted with limited success. Some of these 
strategies are used clinically, while others are still in the experimental stage (Table 
1). Limitation of radiation dose to the ovary was practised but was not very 
effective. In young, sexually mature females with partners, collection of mature 
oocytes for storage or fertilization and subsequent embryo cryopreservation is 
possible. For prepubertal girls, and the majority of young women, preservation of 
fertility remains experimental and harvesting and storage of gonadal tissue before 
commencing cancer therapy is the most promising option (Thomson et al., 2002). 
Table (1): Clinical and experimental strategies for the preservation of 
reproductive function in oncological patients. 
 
Established practices Experimental strategies 
Oophoropexy 
Embryo cryopreservation 
Cryopreservation of oocytes 
Cryopreservation of nuclear material 
Gonadotrophin suppression 
Inhibition of apoptosis 
Cryopreservation of ovarian tissue 
Stem cell research 
Somatic cell cloning 
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1.1. Established practices 
1.1.1.Surgical translocation 
Reducing the radiation dose to the ovary by shielding or removing the ovaries from 
the field of radiation (oophoropexy) may preserve ovarian function (Schlatt et al., 
1999). Oophoropexy involves laparoscopic transposition of the ovaries (with intact 
blood supply) to a position behind the uterus, which acts as a shield, or to the 
paracolic gutters, away from the field of radiation to minimize exposure. The 
ovarian dose received during pelvic nodal irradiation for Hodgkin’s disease can be 
limited by midline oophoropexy from 44 Gy to between 0.22 and 0.55 Gy, and in 
women who are less than 25 years of age at the time of treatment, ovarian failure 
is infrequent. However, even where ovarian function is preserved oocyte retrieval 
with assisted reproduction and surrogacy may be required to achieve pregnancy 
as the uterus may also have been damaged by the radiation therapy. This may 
compromise the ability of the women to carry a pregnancy to term (Thomson et al., 
2002). 
 
1.1.2.Embryo cryopreservation 
The only strategy currently available for preservation of female fertility is 
cryopreservation of embryos. Mature oocyte retrieval and in vitro fertilization (IVF) 
may be offered to women before treatment of cancer. Embryo banking has the 
advantage that it allows a number of embryos to be stored without the need for 
further IVF cycles; however, this requires the patient to have a partner or to use 
donor sperm. On average, 10 oocytes are collected per cycle, limiting the number 
of embryos available for cryopreservation and the overall live birth rate from a 
single cycle of treatment is 11% (Porcu et al., 1997). 
 
1.2. Experimental strategies 
1.2.1. Cryopreservation of oocytes 
Cryopreservation of oocytes is an alternative possibility for women without a 
partner but is much less successful, with less than one baby born per 100 oocytes 
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stored and as such remains experimental (Atkinson et al., 1994). 
The main disadvantage of embryo cryopreservation or oocyte storage is 
requirement for superovulation with gonadotrophins that will inevitably delay the 
commencement of cancer therapy. Also, the high levels of estrogen induced may 
be deleterious in some cancers. Furthermore, this procedure should only be used 
in adult patients (Thomson et al., 2002). 
 
1.2.2. Cryopreservation of nuclear material 
Both second Polar Bodies (2PBs) and Female Pro-nuclei (FPNs) are sub-cellular 
components of the zygote. They are membrane-bound nuclear materials, free of 
meiotic microtubings or ooplasmic organelles, and more importantly, contain a full 
haploid complement of female chromosomes. In addition, they are smaller in 
volume and less complex in composition than oocytes, and could be less sensitive 
to cryoinjury. So, if these components can be safely cryopreserved, it may serve 
as an alternative method to preserve female fertility. However, the potential in this 
new approach for female fertility preservation still relies heavily on the efficiency of 
both cryopreservation and nuclear transfer of the thawed 2PBs or FPNs. Recently, 
He et al 2003, has proven that FPNs or 2PBs removed from a mouse two-
pronuclei zygote can be cryopreserved–thawed and later used to generate 
embryos leading to live births. However, in mice, FPNs can be accurately selected 
based on their proximal location to the 2PBs and its small size relative to the male 
pronuclei. Unfortunately, in human zygotes, both female and male pronuclei are 
not distinguishable and can easily be confused. Clinically, a mistaken transfer of 
the wrong pronuclei could lead to major problems because it has been shown in 
mice that a zygote requires both a male and female pronuclei to develop to full 
term (He et al., 2003). 
 
1.2.3. Gonadotrophin suppression 
The mechanism of cytotoxic chemotherapy and radiotherapy induced gonadal 
damage is uncertain and may differ in males and females, between different 
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modalities of therapy and individual drugs. In contrast to older women, the 
prepubertal women appear to be more resistant to the cytotoxic effects of 
chemotherapy. Consequently it was hypothesized that inducing a prepubertal 
milieu during chemotherapy would decrease the risk of premature ovarian failure. 
Gonadotrophin releasing hormone analogues (GnRH-a) prevent follicular growth 
and mitosis by blocking gonadotrophin induction. Although the exact mechanism is 
uncertain, it may involve direct suppression of GnRH receptors in the ovary, with 
subsequent inhibition of recruitment of small follicles into the proliferating pool as 
well as atresia of the already developed follicles. Although a number of studies 
have demonstrated that GnRH-a inhibit chemotherapy-induced ovarian follicular 
depletion in rodents, there remains uncertainty about applicability in the human, 
particularly as the human ovary has significantly fewer numbers of GnRH 
receptors in the ovary (Glode et al., 1981). Ataya et al. demonstrated that GnRH-a 
co-treatment protected the Rhesus monkey from cyclophosphamide induced 
ovarian damage by significantly reducing follicular decline compared with 
cyclophosphamide alone (Ataya et al., 1995). These findings are supported by 
clinical studies which demonstrated that co-treatment of GnRH-a with 
chemotherapy resulted in premature ovarian failure (POF) in one out of 28 (3.6%) 
compared with 26 out of 40 (65%) in the group treated with chemotherapy alone 
(Blumenfeld et al., 1996). Adjuvant treatment with GnRH-a to limit the gonadal 
toxic effects of otherwise successful treatment regimens is potentially attractive. 
However, this must be viewed with some caution as although GnRH-a provided 
some protection against cyclophosphamide, no advantage was conferred against 
irradiation-induced damage. This may be in part explained by the different 
mechanism of gonadal damage induced by radiotherapy, namely, the destruction 
of primordial follicles, which are not under the influence of gonadotrophins. The 
judicious use of GnRH-a may play a role in the appropriate patient group, such as 
young women and children subjected to alkylating-agent-based chemotherapy for 
Hodgkin’s disease (Thomson et al., 2002). 
 
1.2.4. Prevention of follicle atresia 
Oocyte loss induced by anticancer therapy has been shown to occur by apoptosis, 
consequently, inhibition of the apoptotic pathways has been explored as a 
mechanism for preventing ovarian failure. Although the exact pathway remains to 
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be elucidated, accumulating data support the role of ceramide in signaling somatic 
cell death. Ceramide is a sphingolipid second messenger derived from 
sphingomyelinase-catalyzed hydrolysis, in addition to de novo synthesis. In turn, 
ceramide is metabolized and phosphorylated to give sphingosine-I-phosphate 
(SIP), which is believed to inhibit apoptosis in somatic cells. The role of the 
sphingomyelin pathway has also been studied in germ cells. Disruption of the 
gene encoding acid sphingomyelinase or treatment with sphingosine-I-phosphate 
attenuates apoptosis of primordial fetal oocytes with increased oocyte numbers 
present at birth. Treatment of mice ooctyes with sphingosine-I-phosphate prevents 
chemotherapy-induced apoptosis in vitro. In vivo administration of sphingosine-I-
phosphate confers resistance to radiation-induced apoptosis in mice, with 
pregnancy rates of 100%. While SIP may herald promise of a new approach to 
preservation of ovarian function, further studies are necessary to explore the 
detrimental effects of such treatment on normal neurological function as deletion of 
sphingomyelinase during normal fetal life leads to the development of Niemann-
Pick-disease-like symptoms in post-fetal life (Morita et al., 2000). 
 
1.2.5. Cryopreservation of ovarian tissue 
Cryopreservation of ovarian tissue is the only option potentially available for pre-
pubertal children and the majority of young women. With this method, immature 
oocytes together with other ovarian cells necessary for development and 
maturation of oocytes can be preserved. This technique would enable not only the 
preservation of female gametes in diverse stages of development but would also 
preserve the endocrine functions of the ovary (Sugimoto et al., 2000). 
 
1.2.6. Stem cell research 
The inner cell mass (ICM) of the 3.5 days post coitum (d.p.c.) mouse blastocyst 
comprises a pool of pluripotent cells, which gives rise to all the differentiated cell 
types that make up the embryo and adult, and many of the extra-embryonic 
tissues. By 4.5 d.p.c. the pluripotent ICM cells that lined the blastocoelic cavity 
have differentiated to form primitive endoderm, an extra-embryonic cell lineage 
which gives rise to both visceral and parietal endoderm. From 4.5 d.p.c. to 6.5 
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d.p.c. the remaining pluripotent cells, referred to collectively as ‘epiblast’, undergo 
extensive proliferation, selective apoptosis and migration to give rise to a columnar 
epithelial monolayer of pluripotent cells termed the primitive ectoderm. 
Remodelling of the pluripotent cell population during this time is accompanied by 
alterations in gene expression and differentiation potential. The primitive ectoderm, 
through the process of gastrulation, gives rise to the mesoderm, ectoderm and 
endoderm of the embryo, germ cells, and the remaining extraembryonic tissue. 
While this represents the normal course of embryogenesis, considerable 
developmental lability is evident from the observation that destruction of up to 85% 
of cells within the mouse embryo prior to organogenesis does not necessarily 
prevent formation of a normal embryo. This property is thought to reside in the 
capacity of pluripotent cells to reprogram their development in response to 
environmental signals. Pluripotent cell lines (embryonic stem or ES cells) can be 
isolated from the pre-implantation mouse embryo and maintained in the 
undifferentiated state in vitro. These cells exhibit gene expression profiles and 
differentiation potentials that are consistent with their embryonic origin, and can be 
used as a model system for the analysis of pluripotent cell biology (Lake et al., 
2000). ES cells are characterized by several features, however, the two key 
properties that make these cells so remarkable are these: 
First: ES cells can be grown in vitro and expanded in number indefinitely in the 
primitive undifferentiated state characteristic of the embryonic cells from which 
they are derived. 
Second: throughout long periods of cultivation in vitro they retain a key property of 
those embryonic cells that is the pluripotency, or the ability to develop into any cell 
type in the adult body (Pera et al., 2000). 
Recently, Schöler and colleagues 2003, showed that mouse embryonic stem cells 
in culture can develop into oogonia that enter meiosis, recruit adjacent cells to form 
follicle-like structures, and later develop into blastocysts (Hübner et al., 2003). The 
reported differentiation happened spontaneously over a period of nearly 50 days. 
Schöler and colleagues used bulk two-dimensional differentiation on tissue culture 
plastic, in which both male and female lines of ES cells yielded oocytes (Geijsen, 
2004). They concluded that it is not surprising that the derivation of oocytes and 
blastocyst-like structures could be accomplished with both female and male ES 
cells. In the absence of appropriate SRY expression in the gonads, male primordial 
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germ cells enter the female pathway and often undergo the first step of oogenesis, 
entering meiotic arrest at prophase I (Hübner et al., 2003). The scope of even the 
more obvious applications envisioned for human cells with these properties is 
breathtaking: new approaches to the study of human embryonic development and 
disorders thereof, such as birth defects and embryonal tumours; access to 
hitherto-unexplored territories of human embryonic gene expression for modern 
genomic data mining; new tools for the discovery of polypeptide growth and 
differentiation factors that might find application in tissue regeneration and repair; 
new means to creating human disease models in vitro for basic research, drug 
discovery and toxicology; a potential answer to the issue of the chronic shortage of 
tissue for transplantation in the treatment of degenerative diseases, and an end to 
the use of immunosuppressive therapy in transplantation, if cloning techniques can 
be used to derive stem cells from a patient’s own tissue; new delivery systems for 
gene therapy (Pera et al., 2000). 
 
1.2.7. Somatic cell cloning 
Somatic cell cloning or somatic cell nuclear transfer is a technique in which the 
nucleus (DNA) of a somatic cell is transferred into an enucleated metaphase-II 
oocyte for the generation of a new individual, genetically identical to the somatic 
cell donor (Wilmut et al., 1997). From a biological and technical point of view, the 
cloning of mammals cannot be established exclusively from individual somatic 
cells in order to create directly from these cells a living being. In mammals, cloning 
requires the oocyte and early blastomeres (embryonic cells). The nuclear genome 
must be removed from the oocyte, “by microsurgical procedures” thus being 
enucleated. What remains is the ooplasmic envelope of this oocyte into which the 
nucleus from an embryonic or adult cell is transferred by different methods. 
Enucleated oocyte with donor genome can be cultured in vitro for several days. 
The cloned embryos are then implanted in the uterus of surrogate females. The 
surrogate mothers give birth to offspring, which are genetically identical with the 
original donor cells (Illmensee, 2001). 
In 1997, a Scottish research group reported the birth of a mammal cloned for the 
first time from a somatic cell of an adult animal. The cloned sheep “Dolly” 
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originated genetically from an ewe’s udder cell. In the meantime, “Dolly” has given 
birth to viable and healthy offspring (Wilmut et al., 1997). The success of cloning 
an entire animal from a differentiated adult cell demonstrated that genes 
inactivated during tissue differentiation can be re-activated by a process called 
nuclear reprogramming that means the reversion of a differentiated nucleus back 
to a totipotent status. Somatic cloning may be used to generate multiple copies of 
genetically elite farm animals, to produce transgenic animals for pharmaceutical 
protein production or xeno-transplantation, or to preserve endangered species. 
With optimisation, it also promises enormous biomedical potential for therapeutic 
cloning and allo-transplantation. In addition to its practical applications, cloning has 
become an essential tool for studying gene function, genomic imprinting, genomic 
re-programming, regulation of development, genetic disease, and gene therapy, 
as well as many other topics (Tian et al., 2003). 
Illmensee, 2001 mentioned a number of risk factors that may cause detrimental 
effects on normal development of cloned mammals: 
· Cloning’s low efficiency. Currently the efficiency for nuclear transfer is between 0-
10%, i.e., 0-10 live births after transfer of 100 cloned embryos. 
· Alterations in number and structure of chromosomes (aneuploidy, deletions, 
inversions, and translocations). 
· Alterations in telomeric regions of chromosomes (shortening of 
TTAGGGTTAGGG repeats). 
· Alterations in methylation of genes (imprinting, IGF2 and IGF2R). 
· Epigenetic changes of gene activity. 
· Point mutation of genes. 
· Influence of culture conditions on somatic donor cells and cloned embryos (large 
offspring syndrome). 
· Pre- and postnatal congenital malformations. 
 
2. History of cryopreservation 
The first reports on the cryopreservation of different tissues were published as 
early as 1776 (Luyet and Rapatz, 1970). More than 200 years ago, the Scottish 
surgeon and anatomist, John Hunter, pioneered cryopreservation in the hope that 
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tissues could be revived after a prolonged period of suspended animation. Hunter 
speculated that life could be rekindled after freezing of the human body. Several 
attempts were made to cryopreserve living cells and tissues earlier this century, 
but they met with little success until cryoprotectants were discovered in a London 
laboratory (Oktay et al., 1998). Important milestones on the road to modern 
cryopreservation techniques are shown in Table 2 (Ludwig et al., 1999) and 
include studies on cryopreservation and subsequent thawing of rabbit embryos 
(Chang, 1948), which resulted in the first reported pregnancy by this means. The 
pioneering attempts to cryopreserve gonadal tissue were discovered in 1950s 
when biologists successfully grafted rodent ovarian and testicular tissues after 
freezing and thawing in a glycerol solution. Although these tissues were implanted 
without vascular anastomosis, follicle development and spermatogenesis resumed 
in castrated host animals and in some cases the females were mated and 
delivered small litters (Nugent et al., 2000). Chang was also one of the first 
authors to describe better survival rates of fertilized compared with non-fertilized 
oocytes in rabbits (Chang, 1953). The first pregnancy after cryopreservation of a 
human embryo ended in abortion (Trounson and Mohr, 1983). The first deliveries 
were reported in 1984 (Zeilmaker et al., 1984). A later report demonstrated that a 
genuine opportunity exists for successful ovarian tissue banking in mammals 
(Gosden et al., 1994). The main problem of the cryopreservation procedures is the 
damage to cells and tissues, i.e. the formation of intracellular ice crystals and cell 
destruction. This has been extensively described (Mazur, 1990). For each cell, 
there exist an optimal cryopreservation procedure, defined by the cryoprotectant 
used, and the freezing and thawing protocol. However, advances in 
instrumentation and automation to control freezing rates finely and a better 
theoretic understanding of cryobiology have helped to underpin progress in the 
banking of frozen cells (Oktay et al., 1998). Until now, the pregnancies and births 
yielded by cryopreservation of unfertilized prophase I and metaphase II oocytes 
have been limited. More experience has been gained using pronuclear stage 
oocytes and embryos. Intracytoplasmic sperm injection (ICSI) and pre-implantation 
genetic diagnosis (PGD) with the necessary embryo biopsy have introduced a new 
dimension to the different areas of cryopreservation (Ludwig et al., 1999). 
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Table 2: Review on the historical data of cryopreservation (Ludwig et al., 
1999). 
Author(s) Date Subject  
 
Spallanzani 
 
Ponchet 
Jahnel 
 
Chang 
Chang 
 
Polge et al. 
 
Smith and 
Polge 
Bunge and 
Sherman 
Chang 
 
Ferdows et al. 
 
Sherman and 
Lin 
Parrott 
 
Mazur 
 
Whittingham 
 
Wilmut 
 
 
1776 
 
1866 
1938 
 
1947 
1948 
 
1949 
 
1952 
 
1953 
 
1953 
 
1958 
 
1958 
 
1960 
 
1963 
 
1971 
 
1972a
,b 
 
Freezing of spermatozoa in snow and subsequent 
thawing, and retrieval of motile spermatozoa. 
Freezing of red blood cells. 
Retrieval of human spermatozoa after 
cryopreservation to –196°C or –269°C. 
Freezing of rabbit oocytes. 
Pregnancy after cryopreservation/thawing of rabbit 
embryos. 
Freezing of human and non-human spermatozoa 
using glycerol. 
Cryopreservation and subsequent in vitro culture of 
rabbit zygote using glycerol. 
First established pregnancy after insemination 
using cryopreserved human spermatozoa. 
Better results of cryopreservation after using 
fertilized rather than unfertilized rabbit oocytes. 
Pregnancy after cryopreservation of rabbit oocytes. 
 
Cooling of unfertilized mouse oocytes using 
glycerol and subsequent in-vitro fertilization. 
Pregnancy after ovarian tissue cryopreservation 
and transplantation in mice. 
Theory on cryopreservation damage of cells. 
 
Cryopreservation of mouse embryos at the 
blastocyst stage and birth of living young. 
Cryopreservation of mouse embryos and storage in 
liquid nitrogen. 
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Whittingham et 
al. 
Wilmut and 
Rowson 
Bank and 
Mauer 
Bank and 
Mauer 
Whittingham et 
al. 
Parkening et al. 
 
Maurer and 
Hansemann 
Whittingham 
 
 
Trounson and 
Mohr 
Zeilmaker et al. 
 
 
Cohen et al. 
 
Chen et al. 
 
 
Mandelbaum et 
al. 
Van der Elst 
 
Gosden et al. 
 
1972 
 
1973 
 
1973 
 
1974 
 
1975 
 
1976 
 
1976 
 
1977 
 
 
1983 
 
1984 
 
 
1985 
 
1986 
 
 
1988 
 
1994 
 
1994 
 
Cryopreservation of mouse embryos and 
subsequent delivery of live young. 
Cryopreservation of calf embryos and subsequent 
delivery of live young. 
Cryopreservation of in-vitro fertilized rabbit oocytes. 
 
Using different cryoprotectant (sodium acetate, 
glycerol, PVP, and DMSO). 
Cryopreservation and subsequent pregnancy and 
birth of living young rats. 
Freezing of non-fertilized mouse oocytes, IVF, 
pregnancy and living young. 
Slow and fast two step freezing. 
 
First successful cryopreservation at –196°C of 
mammalian (mouse) oocytes, subsequent 
fertilization, pregnancy and birth of living young. 
Pregnancy and abortion after cryopreservation of a 
human embryo after IVF. 
First deliveries after cryopreservation of human 
embryos. 
 
Cryopreservation of human blastocysts and 
subsequent birth. 
Twin pregnancy and subsequent delivery after 
cryopreservation of human non-fertilized oocytes 
and subsequent IVF. 
Cryopreservation of human immature unfertilized 
oocytes. 
Cryopreservation of human embryos and 
subsequent pregnancy after ICSI. 
Autografting of cryopreserved ovarian tissue and 
subsequent live born in sheep. 
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Al-hassani et 
al. 
Gunasena et al. 
 
Aubard et al. 
 
Tucker et al. 
 
 
Oktay et al. 
 
Sugimoto et al. 
 
 
Salle et al. 
 
 
Candy et al. 
 
1996 
 
1997 
 
1998 
 
1998 
 
 
1998 
 
1999 
 
 
1999 
 
 
2000 
 
Cryopreservation and pregnancies of oocytes at the 
pronuclear stage received after ICSI. 
Autografting of cryopreserved ovarian tissue and 
subsequent live borne in mouse. 
Autografting of cryopreserved ovarian tissue and 
subsequent live borne in rat. 
Pregnancy after cryopreservation/thawing and 
subsequent in vitro maturation of human immature 
oocytes, fertilized by ICSI. 
Retrieval of antral follicles (5 mm) from 
cryopreserved human ovarian graft in mice. 
Observation of antral follicles and corpora lutea in 
addition to small follicles in grafts cryopreserved by 
vitrification. 
Restoration of ovarian steroid secretion and normal 
histologic assessment after freezing, thawing, and 
autograft of a hemi-ovary in sheep. 
Restoration of normal reproductive life span after 
grafting of cryopreserved mouse ovaries. 
PVP= polyvinylpyrrolidone; DMSO= dimethylsulphoxide; IVF= in-vitro fertilization; 
ICSI= intracytoplasmic sperm injection. 
 
3. Indications of ovarian tissue cryopreservation 
Within the ovary the follicular reserve has dual functions: endocrine and exocrine. 
Although the endocrine function can be substituted by hormone replacement 
therapy, the exocrine function is irreplaceable and substitution by a donor oocyte 
does not allow the patient to transmit her genome to her progeny. The follicular 
reserve is a precious asset that diminishes throughout life, and once it is lost, it 
cannot be reconstituted. The key goal of OTCP is to preserve the patient’s fertility 
by protecting her ovarian tissue from threats to the follicular reserve (Aubard et al., 
2000). 
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Three types of threats exist for the ovary, these are: 
1. The first threat to the ovarian reserve and the most inevitable one is the 
passage of time. From the time of birth and even before, the follicular population 
undergoes exponential diminution, which accelerates at approximately the age of 
40 years; the follicles are virtually exhausted at menopause (Aubard et al., 2001). 
2. The second threat to the ovarian reserve is the abnormally rapid destruction of 
the follicular reserves that is observed in certain pathologic conditions responsible 
for premature menopause (Aubard et al., 2001). 
3. The third threat to the ovarian reserve is the iatrogenic one, particularly among 
patients who need to undergo anticancer treatments (Aubard et al., 2001). 
 
3.1.The first threat is the passage of time 
In the embryo, germ cells first appear in the urogenital ridge. These germ cells 
then migrate to the primitive ovary. Once within the ovary, the germ cells multiply 
to form 3.5 million potential oocytes in each ovary. From this time, oocytes are 
held in suspended animation -meiosis- until required for ovulation perhaps 40 
years later (Conway, 2000). Throughout the reproductive life of a woman, only 
approximately 500 follicles achieve maturation with release of a mature oocyte 
(Aubard et al., 2001). The body through apoptosis destroys most germ cells. 
Before birth, two thirds of the 7 million eggs are destroyed, presumably as part of 
quality control mechanism. Between infancy and the age of 40 years, eggs are 
gradually reduced from approximately 1 million to 10,000 in each ovary. Around 
the age of 40 years, the process of egg destruction is accelerated and few are left 
by the age of 50 years (Conway, 2000). 
Might not OTCP constitute an alternative to this enormous wastage? If unilateral 
ovariectomy was performed in a 20-years-old woman and its ovarian cortex was 
cryopreserved, it has been estimated that her age at menopause will only be 
reduced by several years. If the ovarian tissue extracted at the age of 20-years 
was re-grafted in the patient at the time of her menopause (at approximately 45 
years). By this way, the duration of ovarian cycling might then be extended beyond 
the usual age of menopause, thereby delaying the period when hormone 
replacement therapy may be needed. The crucial problem is knowing how long an 
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ovarian cortex that has been cryopreserved and then autografted would be 
functional. By how many years could one thereby delay menopause? We are, for 
the time being, unable to answer this question (Aubard et al., 2000). 
 
3.2.The second threat is the abnormally rapid destruction of the 
follicular reserves ending in premature ovarian failure (POF) 
Coulam et al. examined the medical records of 1,858 women in Rochester, 
Minnesota, and estimated the age-specific incidence of POF to be 1 in 100 by age 
40 and 1 in 1,000 by age 30. In women with primary amenorrhea, the prevalence 
of POF is 10¯28%; in those with secondary amenorrhea, POF occurs in 4¯18%. 
POF is not uncommon, considering these incidence rates and the potential 
underreporting from women who fail to perceive the end of monthly bleeding as a 
medical problem (Coulam et al., 1986). 
The cause of POF is unknown in the majority of women in whom the diagnosis is 
made (karyotypically normal spontaneous premature ovarian failure) and on the 
basis of serial blood sampling it was found that nearly half of these patients have 
ovarian follicles remaining in the ovary. The follicles function intermittently, and 
nearly 20% of patients ovulate during 4 months of observation (Nelson et al., 
1994).  
However, Patients with POF can be classified into 2 different categories as in 
Table 3 (Anasti, 1998) patients with follicle depletion and patients with follicle 
dysfunction. In patients with follicle depletion there is either an initial deficiency in 
primordial follicles or an accelerated rate of follicular atresia that will result in 
premature depletion of the initial follicle endowment. While in patients with ovarian 
follicle dysfunction there are normal appearing oocytes and follicles, yet they fail to 
function properly despite an adequate level of gonadotropins. Thus, the mere 
presence of oocytes does not ensure normal ovarian function. However, in some 
of these situations it is possible to predict premature menopause and, in theory, 
the ovarian tissue from these patients could be extracted for use in a later 
pregnancy. The major difficulty would be precisely estimating the risk of premature 
menopause and the age at which it would occur (Davis, 1996). 
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Table 3: Etiological classification of POF. 
OVARIAN FOLLICLE DEPLETION 
¨ Deficient ovarian follicle number 
Pure gonadal dysgenesis 
Thymus aplasia/hypoplasia 
Idiopathic 
¨ Accelerated follicle atresia 
X-chromosome related 
Turner’s syndrome 
¨ X mosaics 
X deletions 
Galactosemia 
Iatrogenic 
¨ Viral agents 
Auto-immunity 
Oocyte-specific cell-cycle regulation defect 
¨ Idiopathic 
OVARIAN FOLLICLE DYSFUNCTION 
¨ Enzyme deficiencies 
17a-Hydroxylase 
17-20 Desmolase 
Cholesterol desmolase 
Galactose-1-phosphate uridyltransferase 
¨ Auto-immunity 
Lymphocytic oophorotis 
Gonadotrophin receptor blocking immunoglobulins 
Antibodies to Gonadotrophins 
¨ Signal defects 
Abnormal Gonadotrophins 
Abnormal Gonadotrophin receptor 
Abnormal G protein 
Iatrogenic 
Idiopathic (resistant ovary syndrome) 
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3.2.1.X-chromosome abnormalities 
Specific chromosomal defects are associated with impaired ovarian development 
and functions. The most common chromosomal anomalies causing POF are 
Turner’s syndrome (45XO) and superfemale (47XXX). Mosaicism (multiple cell 
lines of varying sex chromosome composition as (45,XO/46,XX, 46,XX/47,XXX) 
and a variety of other X-chromosome anomalies are associated with early follicular 
atresia. Abnormalities of the short arm of the X-chromosome (Xp) generally don’t 
affect the ovarian function whereas deletions or translocations of the long arm (Xq) 
do (Davis, 1996). 
Singh and Carr, examined the ovaries of eight (45,XO) stillborn infants, and noted 
that their germ cells migrated to the gonadal ridge but that primary oocytes 
underwent accelerated atresia during late prenatal life. This and other reports led 
to the postulation of the requirement of 2 intact, active X-chromosomes to ensure 
normal follicle endowment. The deletion or addition of an entire sex chromosome 
in patients with POF adds little to the understanding of the individual genes 
responsible for ovarian function. Thus, investigators have turned to the study of 
patients with POF with subtle X-chromosome deletions and translocations in the 
hope of isolating specific ovarian-regulating genes on the X-chromosome. Eight 
patients with aberrant ovarian function and balanced translocations to an 
autosome t (X;A) have had cells analyzed by molecular methods. On the basis of 
cytogenetic and clinical studies from these patients [t (X;A)] and from patients with 
deletions of the X-chromosome, a “critical region” for normal ovarian function has 
been proposed for Xq13-q26. Additional reports have suggested that a gene 
(POF1) localized to Xq21.3-q27 or within Xq26.1-q27 may be important in defining 
ovarian function. Powell et al. using molecular techniques discovered a second 
gene (POF2) of paternal origin located more proximal to the Xq locus at Xq13.3-
q21.1. Of clinical interest is the younger onset of ovarian dysfunction in those 
patients with deletions in the POF2 region as opposed to individuals with POF1 
deletions. This supports the theory that these regions (POF1 and POF2) are 
distinct from one another. Although it is possible that these translocations and 
subtle deletions may lead to POF by disrupting normal meiosis, a positional effect 
in which the functions of specific ovarian regulatory genes are changed as a result 
of their altered location may also cause ovarian failure. Future analysis, using 
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sophisticated molecular techniques, will permit further delineation of the specific 
regions and genes responsible for X-chromosome related POF (Anasti, 1998). 
All patients under the age of 30 who have been assigned the diagnosis of ovarian 
failure on the basis of high gonadotrophins must have a karyotype determination. 
The presence of mosaicism with Y chromosome requires excision of the gonadal 
areas because the presence of any testicular component within the gonad carries 
with it a significant chance of malignant tumour formation. These are highly 
malignant secondary tumours from germ cells: gonadoblastomas, dysgerminomas, 
yolk sac tumours, and choriocarcinomas. As approximately 30% of patients with Y 
chromosome will not develop signs of virilization, therefore even the normal 
appearing adult women with elevated gonadotropin levels must be karyotyped 
(Speroff et al., 1999). 
3.2.2.Galactosemia 
Galactosemia is a rare autosomal recessive disorder due to a deficiency in the 
enzyme galactose-1-phosphate uridyltransferase (GALT). These patients develop 
hepatocellular, ocular, renal, and neurological damage as a result of the 
accumulation of galactose and its metabolites. According to one study, 81% of the 
47 affected female patients developed ovarian failure, with primary amenorrhea 
noted in 8 patients, and the majority experienced POF shortly after puberty 
(Waggoner et al., 1990). There is controversy as to the ovarian pathophysiology of 
these disorders. In the murine model, gestating rats fed a high-galactose diet 
during the premeiotic phase of fetal oogenesis formed reduced numbers of 
oocytes. This suggests that the ovarian failure in patients with galactosemia is due 
to a galactose-induced decrease in the initial number of oogonia (Anasti, 1998). 
However, an autopsy report of a neonate who had galactosemia revealed normal 
ovarian histology, implying that accelerated follicle atresia depletes the oocytes 
after birth and before puberty (Levy et al., 1984). Furthermore, ovarian biopsy in a 
patient with galactosemia and POF disclosed primordial follicles but no follicle 
growth or development. There is similar confusion about the effect of galactosemia 
on the glycosylation of gonadotropins, hence reducing their biologic activity. A 
report found that the FSH isoforms from female galactosemic sera had a neutral 
isoelectric point. This neutral form of FSH was found to have higher affinity for its 
receptor, but it was unable to stimulate adenylate cyclase (Prestoz et al., 1997). 
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Other investigators have found normal biologic activity of the gonadotropins from 
galactosemic patients. A genetic marker has been identified in some patients with 
galactosemia, GALT 188Q (Kaufmann et al., 1994). Individuals heterozygous for 
GALT 188Q mutations are not at increased risk of developing ovarian dysfunction. 
Thus, the exact mechanism (follicle depletion, follicle dysfunction, or abnormal 
gonadotropins) of ovarian failure in galactosemic patients has yet to be elucidated 
(Anasti, 1998). 
3.2.3.Auto-immune POF 
A link between POF and other autoimmune diseases is well established as 
mentioned in (Table 4) (Anasti, 1998). 
Table 4: Autoimmune diseases associated with POF  
 
¨ Auto-immune thyroid disease  
¨ Adrenal insufficiency  
¨ Vitiligo 
¨ Myasthenia gravis 
¨ Systemic lupus erythematosus 
¨ Hypoparathyroidism 
¨ Autoimmune haemolytic anaemia 
¨ Candidiasis 
¨ Idiopathic thrombocytopenic purpura 
¨ Diabetes mellitus 
 
 The frequency of concurrence of these autoimmune conditions varies somewhat 
between different study populations, although anti-thyroid antibodies are 
consistently the most commonly observed tissue-specific antibodies (Belvisi et al., 
1993). POF is detected in 10-20% of women with idiopathic Addison’s disease and 
often occurs in autoimmune polyglandular syndromes (APS) type I and II (Davis, 
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1996). Circulating anti-ovarian antibodies to ovarian tissue are present in only 
some patients and its low frequency in women with POF may indicate that such 
antibodies are only present during a limited phase of the disease process (Belvisi 
et al., 1993). Several lines of evidence suggest possible roles of the immune 
system in the etiology of POF are summarized in Table 5 (Anasti, 1998). 
Table 5: Evidences suggesting an immunologic role in POF 
 
¨ Association with other auto-immune diseases 
¨ Presence of circulating antibodies 
Antiovarian antibodies 
Gonadotropin receptor antibodies   
Steroid cell antibodies 
Zona pellucida antibodies 
Other organ- and non-organ-specific antibodies 
¨ Histologic evidence of oophoritis 
¨ Association with infectious etiologies  
¨ Altered cell-mediated immunity 
¨ Recovery of ovarian function after immunosuppressive therapies 
¨ Murine neonatal model of thymectomy-induced ovarian failure 
 
A postulated autoimmune mechanism for the development of POF has been 
antibodies against the FSH or LH receptor (Davis, 1996). All of the cited studies 
used non-human gonadotropin receptors in their search for receptor antibodies 
and thus suffer from a potentially fatal flaw in experimental design. An important 
work by several investigators has suggested that human gonadotropin receptors 
are species specific, binding human gonadotropins with higher affinity than 
nonhuman ligand. Thus, human receptors may exhibit species-specific affinity for 
human antibodies. On the basis of this premise, Anasti et al., used a recombinant 
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human gonadotropin receptor bioassay (LH and FSH) to identify immunoglobulin 
G (IgG) antibodies to gonadotropin receptors. After testing the IgG extracted from 
the sera of 38 patients with POF and 14 controls, they were unable to demonstrate 
the existence of an IgG-inhibiting immunoglobulin. The data thus remain 
inconclusive as to the existence of an inhibiting antireceptor antibody as a cause 
of POF (Anasti et al., 1995).  
 
3.2.4.Infections 
The true incidence of ovarian failure due to viral illness is unknown, however 
Investigators noted an incidence of oophoritis of 3-7% in patients who contracted 
mumps during an epidemic, with an inconsistent onset of oophoritis in relation to 
infection. Cytomegalovirus-related oophoritis has been described in patients with a 
compromised immune system such as caused by AIDS or lymphoma and in 
transplant recipients receiving anti-rejection drugs (Anasti, 1998). In a 
retrospective review of medical histories in patients with POF, Rebar and Connolly 
noted that 3.5% of patients had indicated a previous infection such as varicella 
and other infections such as shigellosis or malaria (Rebar and Connolly, 1990). 
 
3.2.5.Enzyme deficiencies 
Several specific enzyme defects can disrupt estrogen synthesis, resulting in 
pubertal delay, primary amenorrhoea, and elevated gonadotropin levels despite 
the existence of normal-appearing primordial follicles in the ovary. Defects in the 
cholesterol desmolase, 17a-hydroxylase, 17-20 desmolase, and aromatase 
enzymes can cause these clinical and histological abnormalities. Patients deficient 
in cholesterol desmolase are unable to produce any biologically active steroids 
and thus rarely survive to adulthood. Patients with 17a -hydroxylase deficiencies 
develop hypertension, hypokalemia, and ovarian failure secondary to impaired 
adrenal and ovarian steroid synthesis. Although the same p450 cytochrome 
complex as 17a-hydroxylase catalyzes it, 17-20 desmolase deficiencies can occur 
without a concomitant defect in17a-hydroxylase. Although these patients present 
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with POF, they exhibit no clinical manifestations of adrenal insufficiency (Yanase 
et al., 1990). 
Galactose-1-phosphate uridyltransferase (GALT), as discussed earlier, induces 
POF by an as yet undefined mechanism. Studies suggest that GALT deficiency 
may cause POF by follicle dysfunction, abnormal gonadotropin bioactivity, or 
accelerated oogonial atresia. Because of the rarity of these enzyme disorders, 
there is a paucity of correlating histologic information (Anasti, 1998). 
 
3.2.6.Signal defects 
Stimulation of the G-protein-coupled gonadotropin receptors induces second 
messengers that initiate specific cellular functions. Defects in the gonadotropins or 
their receptors could result in ovarian failure. Although they are not associated with 
elevated gonadotropins, several inherited defects of gonadotropin synthesis and 
secretion causing hypogonadism have been described. These include mutations 
of the FSH-subunit, KAL, and DAX-1 genes. The KAL mutation, which results in 
Kallman’s syndrome, and the DAX-1 mutation, which results in X-linked adrenal 
hypoplasia, causes a deficiency of GnRH. In addition, the DAX-1 mutation results 
in defective pituitary production of gonadotropins (Layman et al., 1997). 
3.3.The iatrogenic threat, particularly among patients who need to 
undergo anticancer treatments: 
Advances in the diagnosis and treatment of childhood, adolescent and adult 
cancer have greatly enhanced the life expectancy of premenopausal women with 
cancer. As a result, there is a growing population of adolescent and adult long-
term survivors of childhood cancer (Donnez and Bassil, 1998). 
Frequently, however, the price that is paid by female patients for successful 
cancer treatment is ovarian failure and infertility. Most infertility associated with 
cancer results from the treatment and not the disease. The main lines of treatment 
against cancer are surgery, radiotherapy and chemotherapy (Meirow et al., 1999). 
After the success of animal experiments, reports have been published about 
ovarian tissue cryopreservation for such patients. The storage of ovarian tissue 
may provide a means of restoring long-term fertility to patients undergoing 
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treatment that may irreversibly damage the oocyte population. Also, tissue 
obtained before any systemic or local treatment may provide more security with 
regard to genetic abnormalities for future offspring (Donnez and Bassil, 1998). 
 
3.3.1.Surgical treatment 
Surgical interventions that either remove the ovaries or alter blood flow to them 
affect estrogen level as well as gonadotropin (FSH and LH) levels. Gynecologic 
procedures, such as bilateral salpingo-oophorectomy and pelvic exenteration, 
result in a sudden disruption of estrogen production and a dramatic change in the 
hormonal dynamics. It can be disrupted also during any major abdominal surgery, 
if the blood flow to the ovaries is altered and follicles die (Lin et al., 1999). In some 
cases it is surgically necessary to remove part or all of the ovarian tissue, as, for 
example, with ovarian tumors. If a curative ovariectomy is performed because a 
primitive or metastatic neoplasia has involved the ovary itself, zones of ovarian 
cortex that appear normal at a macroscopic level may exist beside the tumor. As 
this ovarian cortex is lost to the patient in any case, its freezing may be useful. The 
choice of cortical tissue to cryopreserve must be made in consultation with a 
pathologist, and the pathologist should be given the entire ovarian medulla. If the 
histopathological analysis of the medulla and cortex has negative results, 
autografting appears to be possible. In other cases the ovary is not cancerous, but 
the risk of microscopic or future involvement has led to the decision to perform 
ovariectomy as prophylaxis. Here also, freezing of ovarian tissue appears a good 
solution. Patients with certain mutations of BRCA1 and BRCA2 genes has a 
greatly increased risk of developing ovarian cancer, the risk is sufficiently high that 
prophylactic ovariectomy is recommended at approximately age of 35 years. One 
could certainly consider removing one ovary from the patient at approximately age 
of 20 years, which would enable the woman to have an available reserve of 
ovarian tissue that she could use later at any age (Aubard et al., 2001). 
The indications for OTCP in cases of malignant disease are listed in Table 6 
(Donnez and Bassil, 1998). However, in the case of gynecological malignancies, a 
conservative fertility approach is valuable only if the uterus can be spared during 
surgery. This includes cases of early cervical carcinoma, early vaginal carcinoma, 
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ovarian tumours of low malignancy, and some selected cases of unilateral ovarian 
carcinoma, stage IA1 (Donnez and Bassil, 1998). 
 
Table 6: Indications for cryopreservation of ovarian tissue in cases of 
malignant disease. 
 
¨ Extra-pelvic diseases 
Bone cancer (osteosarcoma-Ewing’s sarcoma) 
Thyroid and kidney cancers 
Breast cancer 
Melanoma 
Neuroblastoma 
Bowel malignancy 
¨ Pelvic diseases 
Non-gynecological malignancy 
Pelvic sarcoma 
Sarcoblastoma 
Rhabdomyosarcoma 
Sacral tumours 
Recto-sigmoid tumours 
Gynecological malignancy 
Early cervical carcinoma 
Early vaginal carcinoma 
Early vulvar carcinoma 
Selected cases of ovarian carcinoma 
Ovarian borderline tumours 
¨ Systemic disease 
Hodgkin’s disease 
Non-Hodgkin’s lymphoma 
Leukemia 
Melanoblastoma 
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3.3.2. Radiation Therapy  
Total body, abdominal or pelvic irradiation may cause ovarian and uterine 
damage. This damage may be produced directly by destroying ovarian follicles or 
indirectly by altering blood flow to the ovaries and uterus, causing vascular 
fibrosis. The degree of impairment is related to radiation dose, fractionation 
schedule and age at time of treatment as mentioned in Table 7 (Speroff et al., 
1999; Lin et al., 1999). The number of primordial follicles present at the time of 
treatment and dose of radiotherapy will determine the fertile window and dictate 
the age at menopause. This means that the younger the child at the time of 
radiotherapy the larger the oocyte pool and hence the later the menopause. The 
human oocyte is sensitive to radiation, with an estimated LD50 of less than 4 Gy 
(Wallace et al., 1989b). A permanent menopause may be induced in women over 
40 years following treatment with 6 Gy while significantly higher doses are 
required to destroy the oocyte pool completely and to induce ovarian failure in 
younger women and children (Howell and Shalet, 1998). Ovarian failure has been 
observed in 97% (37 of 38) of females following whole abdominal irradiation in 
childhood (20-30 Gy). Of the 37 women, primary amenorrhoea was reported in 
71% and premature menopause (median age 23.5 years) in the remainder 
(Wallace et al., 1989a). 
Total body irradiation (TBI) either alone or in combination with cyclophosphamide 
(as conditioning for bone marrow transplantation) is associated with infertility. All 
women conditioned with total body irradiation (9.2-15.75 Gy) and 
cyclophosphamide (120 mg/kg) before bone marrow transplantation for leukemias 
develop amenorrhoea, with recovery seen in only nine of 144. TBI was found to be 
the only factor significantly influencing ovarian failure-the younger the age of the 
patient at the time of treatment the greater the probability of recovery of ovarian 
function (Sanders et al., 1988). In a long-term follow-up of 708 women, median 3 
years (range: 1-17), after bone marrow transplantation, 532 had received TBI (10-
15.75 Gy, single exposure or fractionated) and 176 were treated with 
cyclophosphamide (200 mg/kg), alone or with busulphan (16 mg/kg), as 
conditioning therapy. Ovarian failure was observed in 90% of patients following 
TBI and 68% following chemotherapy among an additional 82 patients treated 
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prepubertally. With the same regimens, ovarian failure was reported in 72% 
(Sanders et al., 1996). 
 
Table 7: The risk of sterilization according to the patient’s age and radiation 
dose 
 
Ovarian Dose Strelization Dose 
 
60 rads 
150 rads 
250-500 rads 
500-800 rads 
Over 800 rads 
 
No effect 
Some risk over the age of 40 
Ages 15-40: 60% sterilized 
Ages 15-40: 60-70% sterilized 
100% permanently sterilized 
 
It was demonstrated that uterine function may be compromised following 
radiotherapy and reduced uterine volume and decreased elasticity of uterine 
musculature, were found in girls receiving pelvic, abdominal and total body 
irradiation prepubertally (Bath et al.1999). Disruption of uterine characteristics may 
compromise implantation and continuation of pregnancy. Although successful 
pregnancies following radiotherapy are reported, the incidence of spontaneous 
miscarriage, premature delivery and intrauterine growth retardation is significantly 
increased (Wallace et al., 1989a; Sanders et al., 1988). Following whole 
abdominal irradiation (20-30 Gy) in childhood, all pregnancies occurring in women 
with preserved ovarian function resulted in mid-trimester miscarriage. In studies 
exploring the role of exogenous sex steroids, women with premature ovarian 
failure following TBI for childhood leukemias treated with physiological sex steroid 
replacement therapy have shown an increase in uterine volume and endometrial 
thickness (Bath et al.1999). This is encouraging for future fertility prospects and 
may be a useful way of improving uterine function when assessing these women 
for assisted reproductive techniques (Thomson et al., 2002). 
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3.3.3. Chemotherapy 
The efficacy of chemotherapeutic agents depends upon their ability to destroy 
rapidly dividing cells. Thus, the initial phase of ovarian destruction involves 
proliferating granulosa and theca cells, which are the primary components of 
developing follicles. Other chemotherapeutic agents, especially alkylating agents, 
destroy cells by altering cellular DNA. This alteration of genetic material by these 
agents may account for the second phase of ova destruction, which includes non-
proliferating primordial follicles (Anasti, 1998). 
The literature on the effects of chemotherapy on ovarian function shows that 
alkylating agents are most likely to have an impact on reproductive function and 
are most closely linked with infertilty, although other agents also affect ovarian 
function as shown in Table 8 (Lin et al., 1999). The detrimental effect of a given 
chemotherapeutic agent on the ovaries can occur through impairment of follicular 
maturation and/or depletion of primordial follicles. The risk of permanent ovarian 
damage and dysfunction is dependent upon the patient’s age, chemotherapeutic 
agent (particularly the alkylating agents), drug dose, treatment schedule and 
duration, regimen combination, and time since treatment completion. Age appears 
to be the most important factor. Patients older than 40 years, experience a 
consistently higher rate of amenorrhea compared with younger patients. Rates 
vary from 21% to 71% in the younger age group and from 49% to 100% in the 
older group (Blumenfeld et al., 1999). 
Unlike their older counterparts, prepubertal patients are relatively resistant to the 
ovarian effects of alkylating agents. This apparent resistance of the prepubertal 
ovary to the effects of chemotherapy has led investigators to attempt to suppress 
ovarian follicle growth during or before treatments (Anasti, 1998). Whereas the 
cytotoxic-induced damage is reversible in other tissues of rapidly dividing cells 
such as bone marrow, gastrointestinal tract, and thymus, it appears to be 
progressive and irreversible in the ovary, where the number of germ cells is 
limited, fixed since the fetal life, and cannot be regenerated (Blumenfeld et al., 
1999). Chemotherapy does not appear to have any significant long-lasting adverse 
effect on uterine function. Successful pregnancy with no increased risk of 
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miscarriage, and healthy offspring are reported following treatment with multi-
agent chemotherapy regimens (Salooja et al., 2001). 
 
Table 8: Chemotherapeutic agents that affect sexual or reproductive 
function 
 
¨ Alkylating agents 
Busulfan 
Chlorambucil 
Cyclophosphamide 
Melphalan 
Nitrogen mustard 
¨ Antimetabolites 
Cytosine arabinoside 
5-Fluorouracil 
Methotrexate 
¨ Antitumour antibiotics 
Doxorubicin 
Plicamycin 
Dactinomycin    
¨ Plant products 
Vincristine 
Vinblastine 
¨ Miscellaneous agents 
Procarbazine  
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4. Cryobiology of gonadal cells and tissues 
4.1. Freezing injury 
Although cooling retards the process of degradation and therefore preserves the 
structure of cells, it can destroy their function irreversibly when it goes below the 
freezing temperature without cryoprotective agents (CPAs). When cells are cooled 
to temperatures between –5°C and –15°C, ice crystal formation is induced in the 
extra-cellular medium. As the temperature decreases further, the amount of ice 
increases, the solutes concentrate in the extra-cellular medium creating an 
osmotic gradient, and there is net water movement from the cytoplasm to the 
extra-cellular medium causing cellular shrinkage and dehydration. Cells 
undergoing cryopreservation are therefore; prone to damage induced by the 
formation of intracellular ice and from the build-up of salts in the cells as they 
dehydrate. Moreover significant freezing injury can occur during the thawing (re-
expansion) phase because of the changes in the composition of the surrounding 
milieu, possibly mediated by temporary leakage of the plasma membrane (Picton 
et al., 2000). 
4.2.Cryoprotective agents 
The discovery of CPAs and the birth of modern cryobiology, despite a short 
history, have significantly affected the course of long-term storage of tissues and 
cells in various scientific disciplines (Picton et al., 2000). CPAs are essential for 
cryopreservation but are potentially toxic at high concentration. Therefore, defining 
the required, and non-toxic concentrations of CPAs is the primary challenge that 
must be met in order to vitrify organs successfully. Not only does this toxicity 
prevent the use of fully protective levels of these additives, but it may also 
manifest in the form of cryoinjury over and above the classical cryoinjury. 
Therefore, the main target of any vitrification protocol must be the suppression of 
toxicity without any loss of CPAs effectiveness. Many different chemicals, such as 
alcohols, amines, sugars, and proteins can achieve protection of cells and tissues 
from damage during freezing and thawing. An effective CPA must have a number 
of key properties: high water solubility to depress the freezing point, high 
permeability to minimize the osmotic gradient, and low toxicity (Liebermann et al., 
2002a). CPAs commonly used for vitrification of living cells, embryos and tissues 
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include dimethyl sulphoxide (DMSO), 1,2-propanediol (PROH), polyethylene 
glycol, dextrose and acetamide. DMSO is the primary component because of its 
great glass-forming ability, permeability and low toxicity. The addition of acetamide 
in the cryoprotectant mixture also lowers the toxicity of DMSO not only because of 
dilution, but also because it complexes with DMSO, preventing it from denaturing 
fructose diphosphatase and similar enzymes. By similar mechanisms, the 
presence of DMSO reduces the damaging effects of acetamide. Dextrose is 
thought to also specifically neutralise the toxicity of DMSO by preventing its 
irreversible binding to proteins (Friedler et al., 1988). The CPAs penetrate the cell 
membrane and are thought to stabilise intracellular proteins, reduce the 
temperature at which cells undergo lethal intracellular ice formation and moderate 
the impact of concentrated intra and extra-cellular electrolytes. Glycerol was used 
in the past but now the previous CPAs supersede it. These CPAs have high water-
solubility, rapid penetrability and produce less osmotic damage at high 
concentrations normally used in cryopreservation protocols. However, their effects 
on cellular viability are still largely unknown (Picton et al., 2000). The toxicity of 
CPAs depends on the inherent characteristics of the chemical itself, duration of 
exposure, and temperature. Incubation time is as important as the concentration of 
the CPAs and depends on the type of the CPAs utilized and the incubation 
temperature. DMSO penetrates human ovarian tissue more rapidly than PROH at 
4°C, while at 37°C, cell penetration is similar for both of them, but they are more 
toxic at this temperature (Demirci et al., 2002). However, rapid permeation of cells 
with CPAs at low temperatures is desirable to minimize toxicity. For example, 
CPAs exposure in mature oocytes has been implicated in alterations in the 
cytoskeleton, microtubular structure, and spindle organization. Such effects may 
disrupt the normal organization and traffic of molecules and organelles, impair 
embryonic development and increase the incidence of aneuploidy and other 
chromosomal anomalies. Also, CPAs exposure has been shown to promote the 
passive influx of Ca²+ across the plasma membrane, possibly by stimulating the 
release of Ca²+ from storage sites in the mitochondria and endoplasmic reticulum. 
Such increases in the intracellular Ca²+ can lead to parthenogenetic activation of 
mature oocytes and are known to activate intracellular phospholipases, proteases, 
ATPases and endonucleases, resulting in altered plasma membrane integrity, 
denaturation of cytosolic proteins, and chromosomal fragmentation, all of which 
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can lead to irreversible cell injury and apoptosis. In addition to the potential 
cytotoxic effects of CPAs exposure, they are hyperosmotic and penetrate cells 
more slowly than water. Video microscopy of human oocytes has revealed that 
CPAs exposure causes 40% shrinkage of cellular volume as water is withdrawn 
down the osmotic gradient, followed by a return to normal volume as the CPAs 
penetrates the cell. When the oocyte is returned to the isotonic solution after 
thawing, there is an inward osmotic flux with the possibility of excessive swelling to 
140-150 % of the physiological volume. These volumetric changes may contribute 
to the mechanism for the induction of cytogenetic damage during cryopreservation 
of mature oocytes, and in extreme cases, can cause cellular lysis (Picton et al., 
2000). 
Cells naturally contain high concentrations of proteins, which are helpful in 
vitrification (Newton et al., 1998). Antifreeze proteins are mainly glycopeptides and 
probably act by an adsorption–inhibition mechanism to prevent the growth of ice 
crystals. It has been reported that an antifreeze protein from the common yellow 
mealworm beetle, Tenebrio larvae, has higher activity than fish antifreeze proteins. 
Natural antifreeze proteins may prove to be beneficial for ultra-rapid cooling 
(vitrification) in the presence of high concentration of CPAs to eliminate ice crystal 
formation. It was reported that the addition of fish antifreeze glycopeptides to 
vitrifying solutions increases post-thaw viability in cultured immature pig oocytes 
and embryos and appears to preserve cell membrane structural integrity. 
Antifreeze proteins have been found not only in animals but also in plants as well. 
Researchers in York have isolated antifreeze proteins from the taproot of cold-
acclimated carrots (Daucus carota). This protein inhibits the re-crystallization of ice 
and exhibits antifreeze activity. Although antifreeze proteins appear to reduce 
freezing injury and improve cell viability, the practical value and application of 
antifreeze proteins needs further investigation (Poirot et al., 2002). 
 
4.3.Protocols of OTCP 
Unlike cryopreservation of isolated cells, freeze-storage of tissue presents new 
problems because of the complexity of tissue architecture and protocols must 
strike a compromise between the optimal conditions for each different cell type. 
For example, the cooling and warming rates together with dehydration conditions 
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which, result in optimal survival of one cell type may not be ideal for other cellular 
components of the same piece of tissue. In addition, problems can arise when ice 
forms extracellularly, because it can cleave tissues into fragments. Furthermore, 
rapid solute penetration of highly compacted tissue is vital to ensure high final 
concentration of CPAs at temperatures, which will minimise cytotoxicity. These 
requirements necessitate optimisation of freeze/thaw protocols for each cell type, 
as post-thaw survival of reproductive cells and tissues, is profoundly affected by 
both the type of CPAs used and the equilibration time required for CPAs uptake 
and removal. Despite the apparent difficulties compared with single cells, the 
storage of gonadal and particularly ovarian tissue has proved surprisingly 
successful. The suitability of ovarian tissue for freezing is enhanced by the 
developmental plasticity of the tissue as the ovary is capable of functioning even 
when its complement of follicles has been severely reduced such as naturally 
occurs during ageing, after partial ablation or after injury. Furthermore, the cortical 
distribution of primordial follicles permits the preparation of small strips of tissue 
that provide maximal surface area for rapid CPAs penetration as evidenced by 
NMR spectroscopy (Newton et al., 1998). In support of this recommendation there 
is the slow cooling, rapid thawing protocol and the ultra-rapid cooling protocol 
(vitrification). 
4.3.1.Slow cooling, rapid thawing protocol  
Where the cooling rate is fast enough to minimise exposure of cells to high 
intracellular concentrations of electrolyte and slow enough to avoid intracellular ice 
formation. Furthermore, these processes should be carried out in the presence of 
low concentrations of non-permeable osmolytes, such as sucrose and mannitol, to 
act as osmotic buffers against swelling during the addition and removal of CPAs. It 
is a time consuming procedure, and it requires special equipment such as a 
programmable freezer (Picton et al., 2000). Table 9 describes this protocol 
(Gosden et al., 1994). 
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Table 9: Protocol for cryopreserving and thawing human ovarian tissue 
 
 
1. Equilibrate thin slices of ovarian cortex for 30 minutes on ice in buffered 
medium containing cryoprotectant (1.5 M. DMSO), serum 10%, and 0.1 M 
sucrose/mannitol 
2. Load the tissue in cryovials into an automated freezer starting at 0°C and cool 
at 2°C/min to –7°C 
3. Soak for 10 minutes before seeding 
4. Continue to cool at 0.3°C/min to -40°C 
5. Cool at the faster rate of 10°C/min to -140°C 
6. Transfer to liquid nitrogen dewar for storage 
7. Thaw rapidly at ~100°C/min 
8. Wash tissues stepwise in progressively lower concentration of medium 
 
4.3.2.Ultra-rapid cooling (vitrification) protocol  
4.3.2.1.Definition of vitrification 
Vitrification can be defined as a process that produces a glasslike solidification of 
living cells that completely avoids ice crystal formation during cooling. Equally 
important, the vitrification process completely avoids ice crystal formation in 
cryopreserved cells during warming to recover the cells for biological applications 
(Kuleshova and Lopata, 2002). 
4.3.2.2.History of vitrification 
Retrospectively, the phenomenon of vitrification was first investigated and 
described at the turn of the 19th century. The founder of cryobiology, Luyet, 
recognized the potential of achieving an ice free, structurally arrested state for 
cryopreservation 60 years ago and described it in his classical studies (Kuleshova 
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and Lopata, 2002). Luyet wrote that crystallization is incompatible with living 
systems and should be avoided whenever possible. The cooling of small living 
systems at ultrahigh speeds of freezing was considered to be possible, in that it 
could eliminate ice formation and create instead a glass-like (vitreous) state. This 
constituted the origin of the idea of vitrification but not, however, the beginning of 
the vitrification of organs, which was unthinkable at the rapidity of freezing and 
thawing demanded by Luyet (Rall et al., 1987). Subsequently, it was generally 
recognized that supporting solutions for vitrification would be better for the 
preservation of living cells and tissues than would solutions that crystallize and 
hence damage cells during cooling and warming. The procedure for successful 
cryopreservation by vitrification of mammalian embryos and oocytes, including 
human, has been the subject of intense research over many years. In 1985, Rall 
and Fahy showed for the first time that murine embryos could be successfully 
cryopreserved by vitrification (Rall et al., 1985). The initial solution (VS1) was very 
toxic, but those investigators found ways to overcome this problem. In these older 
studies, some elements of slow cooling procedures, rather than modern 
vitrification protocols were used so, researchers can consider Rall and Fahy 
studies as a bridge between vitrification and slow cooling (Kuleshova and Lopata, 
2002). 
4.3.2.3.Vitrification of ovarian tissue 
Cryopreserving oocytes, embryos and ovarian tissues by vitrification has many 
advantages as mentioned in Table 10 (Liebermann et al., 2002a). 
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Table 10: Summary of the primary benefits of vitrification 
 
 
1. Direct contact between cells/tissue and liquid nitrogen 
2. No ice crystallization 
3. Utilizes higher concentration of cryoprotectant that allows shorter exposure 
times to the cryoprotectant 
4. Rapid vitrification/warming 
5. Small volume used provides a significant increase in the cooling rate 
6. Cooling rates from; 15 000°C to 30 000°C/min 
7. Minimizes osmotic injuries 
8. Reduces the time of the cryopreservation procedure (duration from 2 to 10 
min) 
9. Very simple protocols 
10. Eliminates the cost of expensive programmable freezing equipment 
 
However, many variables can affect the effectiveness and success of vitrification 
and have an impact on the biological sample that is cooled from physiological to 
liquid nitrogen temperature (Table 11) (Liebermann et al., 2002a). The two most 
important parameters are the cooling rate and the concentration of the 
cryoprotectants. 
A practical limit to attainable cooling speed exists, as does a biological limit on the 
concentration of cryoprotectant tolerated by the cells during vitrification. Therefore, 
a balance between the maximization of cooling rate and the minimization of 
cryoprotectant concentration is important. To achieve high cooling rates requires 
the use of high concentrations of the cryoprotectant solution, which depresses ice 
crystal formation. A critical concentration is required for vitrification. Furthermore, 
to facilitate vitrification by even higher cooling rates, it is also necessary to 
minimize the volume of the vitrification solution as much as possible (Liebermann 
et al., 2002a). To do that, special carriers are used during the vitrification process. 
These include open pulled straws (OPS) (Oberstein et al., 2002) or the flexipet-
denuding pipette (FDP) (Liebermann et al., 2002c), microdrops (Papis et al., 
2000), electron microscopic (EM) copper grids (Park et al., 2000), hemistraw 
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system (Liebermann et al., 2002b), small nylon coils (Kurokawa et al., 1996) or 
nylon mesh (Matsumoto et al., 2001), and the cryoloop (Liebermann and Tucker, 
2002). These have all been used as carriers or vessels to achieve higher cooling 
rates. To minimise devitrification (the previously vitrified solution freezes upon 
rewarming), thawing must be rapid, because rapid thawing reduces the likelihood 
of devitrification, since the rate of ice crystal growth diminishes and eventually 
disappears totally above a certain rate of heating. The number of nucleation 
centres determines the position of the devitrification curve and the critical heating 
rate. Fahy et al., reported that heating rates no greater than 400-1000°C/min 
should be required to prevent devitrification (Fahy et al., 1984) 
Various research groups have reported the successful vitrification of ovarian tissue 
from mice, rats, Chinese hamsters, rabbits, Japanese apes, cows, and human 
fetuses (Kagabu and Umezu, 2000; Van den Broecke et al., 2001). Vital follicles 
were still detected 4 days after the warming of vitrified fetal rat ovaries (Sugimoto 
et al., 1996). Miyamoto and Sugimoto (Miyamoto and Sugimoto, 1994) vitrified rat 
ovaries and removed the cryoprotectant stepwise. The histological examination of 
the follicles yielded positive results in surface area but revealed degenerative 
changes, such as pyknosis, vacuolization, and cell swelling, in the other remaining 
tissue. The comparison of slow freezing and vitrification of bovine ovarian tissue 
demonstrated, however, that a vitrification protocol (exposure to 5.5 M EG at 22°C 
for 20 min) could be just as effective as slow freezing (Yen et al., 2001). 
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Table 11. Variables of vitrification that can profoundly influence its 
effectiveness. 
 
 
1. Type and concentrations of cryoprotectant (almost all cryoprotectants are 
toxic) 
2. Media used as base media (holding media) 
3. Temperature of the vitrification solution at exposure 
4. Length of time cells/tissue are exposed to the final cryoprotectant before 
plunging into liquid nitrogen 
5. Variability in the volume of cryoprotectant solution surrounding the 
cells/tissue 
6. Device used for vitrification (size of the vapor coat and cooling rate) 
7. Technical proficiency of the embryologist 
8. Quality and developmental stage of the tested cells/tissue 
9. Direct contact of the liquid nitrogen and the vitrification solution containing 
the biological material can be a source of contamination (Bielanski et al., 
2000); and to eliminate this danger, using sterile liquid nitrogen for cooling 
and storage is essential 
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Fig.1. Theoretic options for the use of banked human ovarian tisssue 
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5. Future of the cryopreserved ovarian tissues 
Cryopreservation and banking of human ovarian tissue is now feasible, but the 
problem of ovarian tissue cryopreservation is that of the future of the frozen grafts. 
In theory, there are three possibilities: autotransplantation, xenografting and in 
vitro growth and maturation as shown in Figure 1 (Oktay et al., 1998). 
5.1.Autotransplantation 
Autotransplantation appears, at least in concept, to be a simple and practical 
method for maturation of oocytes in stored ovarian tissue. Cryopreserved ovarian 
tissue can be autografted either orthotopically or heterotopically (Salle et al., 
1999). 
5.1.1.Orthotopic transplantation 
Orthotopic transplantation of cryopreserved ovarian tissue has been successfully 
performed in many animal models. These studies proved that frozen ovarian 
tissue could resume its cyclical function after transplantation without vascular 
reanastomosis, (mouse: Harp et al., 1994; sheep: Baird et al., 1999; human: 
Grischenko et al., 1987) and are capable of becoming pregnant (mouse: Cox et 
al., 1996), live youngs have been born in mice (Gunasena et al., 1997) and sheep 
(Gosden et al., 1994). In the rodent, cyclicity was restored by grafting in 75% of 
the mice and at the same time a similar percentage to that observed in controls 
carrying fresh ovarian grafts (Candy et al., 2000). Even more remarkably, frozen-
thawed fetal mouse ovaries restored cycles to 100% of syngeneic adult 
ovariectomized mice, many of which became fertile (Cox et al., 1996). Studies of 
the sheep ovary have shown that ovarian tissue cryopreservation and orthotopic 
transplantation are feasible in a large species. This is of great interest because 
sheeps are large mammals whose ovarian architecture is very close to that of the 
human women. Furthermore, the ovarian cortex is thick, the size of the ovary 
approaches that of of the human ovary, and the number of subcortical primordial 
follicles is high. Because the whole ovary is too large to be cryopreserved, cortical 
slices were prepared from one organ for freezing to liquid nitrogen temperatures 
using a medium containing DMSO and a slow freeze, rapid thaw protocol. When 
the contralateral ovary was removed 3 weeks later, frozen-thawed and fresh slices 
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of tissue were grafted to opposite sides with 5¯0 delayed absorbable suture to the 
ovarian pedicles. The first ovulations occurred approximately 4 months after the 
second operation (Salle et al., 2002). In a subsequent study, a further set of eight 
sheep was grafted with bilateral frozen-thawed autografts. The ovaries regained 
cyclicity and functioned as the controls for 22 months, until they were removed 
(Baired et al., 1999). Morever, it has been reported that laparoscopic 
transplantation of frozen-banked ovarian tissue beneath the pelvic peritoneum in a 
patient 29 years whose ovarian tissue was previously removed and frozen with the 
slow-freeze technique resulted in ovulation and menstruation 4 months after the 
transplant in response to ovarian stimulation with menopausal gonadotropins 
(Oktay and Karlikaya, 2001). When an intact uterus and functional fallopian tubes 
are present, an orthotopic graft may restore normal fertility. However, the 
orthotopic graft sites are less numerous than in the case of heterotopic graft. The 
peritonium of the broad ligament has not given good results, whereas the 
contralateral ovary and uterus have accepted the graft without problem (Salle et 
al., 1999).  
5.1.2. Heterotopic transplantation  
Where the ovarian tissues can be grafted in different sites outside the pelvis, 
including the rectus muscle, abdominal subcutaneous tissue, the omentum, 
saphenous vein, and under the renal capsule (Salle et al., 1999). 
The ideal site for heterotopic ovarian autotransplantation remains to be 
established. As a potential treatment for the menopause, the site of the graft 
seems not critical and with the advent of in vitro fertilization technology and high-
resolution ultrasound, heterotopic grafting could also potentially form an alternative 
approach for the preservation of fertility (Callejo et al., 2001). 
When fresh and frozen-thawed fetal murine ovaries were transplanted under the 
kidney capsule of adult mice, follicular development was identified in the grafts. 
When ovaries from fetal hamsters were transplanted under the kidney capsule of 
adult hamsters, the number of growing follicles increased after host treatment with 
estradiol or testosterone propionate (Abir et al., 2001). As a clinical application of 
this choice, Nugent et al. grafted fresh ovarian cortical biopsies from nine patients 
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into uterine subserosa. After 14 weeks, the histologic analysis showed preantral 
follicle development. On average, 25% of follicles survived after grafting in 
comparison with the ungrafted controls. The authors attributed the lack of antral 
follicle development to suppression by the patient’s functioning ovaries (Nugent et 
al., 1998). Oktay et al. performed a subcutaneous ovarian transplantation in a 
patient with squamous cell cervical carcinoma (Oktay et al., 2000). Placed in the 
forearm, the graft produced cyclical estrogen for more than a year. No 
spontaneous ovulation occurred, but a percutaneous retrieval after 
gonadotropin/human chorionic gonadotropin administration yielded a mature 
oocyte. Schnorr et al. reported restoration of ovarian/menstrual cyclicity in a 
majority of nonhuman primates after transplantation of 1 mm³ fresh and frozen-
thawed ovarian pieces in the arm (Schnorr et al., 2000). Other work showed that 
gonadotropin administration could increase the survival of ovarian transplants to 
the body wall in mice (Imthurn et al., 2000). 
In another landmark study in sheep, Aubard et al. (Aubard et al., 1999) compared 
the function of heterotopic and orthotopic autografts of frozen-thawed ovarian 
cortex. Fresh and frozen-thawed fragments of ovarian cortex were autografted 
onto the uterine horn of six ewes (orthotopic grafts) and under the skin of the belly 
in nine ewes (heterotopic grafts). In both fresh and frozen-thawed grafts, preantral 
and antral follicles were first detectable 4 and 10 weeks after grafting, respectively, 
but only 5% of the primordial follicles appeared to have survived. Although 
ovulation resumed in most ewes, none of the ewes that were grafted orthotopically 
became pregnant at a synchronized mating. Aubard et al. noted significant 
adhesion formation due to the transplantation procedure, explaining the lack of 
spontaneous conception. Seven months after grafting, immature oocytes were 
retrieved from heterotopic and orthotopic grafts. They were matured in vitro and 
some of them fertilized, but none developed to the blastocyst stage. Although in-
vitro maturation alone might have contributed to the poor embryo development, 
lack of any blastocyst formation indicates the necessity for further study of the 
quality of the embryos generated from transplanted frozen-thawed ovarian tissue.  
Although autografting into an orthotopic or heterotopic site seems most promising, 
its clinical application is problematic because it carries the following risks: 
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* The potential risk of disease transmission. The grafts can transmit viruses 
including human immunodeficiency virus (HIV), and hepatitis viruses. 
* The risk of cancer recurrence (Shaw et al., 1996). There is a legitimate concern 
regarding the potential for reseeding cancer cells with ovarian transplantation, 
depending on the type of cancer. Although many cancer types never metastasize 
to ovaries, leukemias are systemic in nature and pose a greater risk to the 
recipient. Likewise, neuroblastomas pose a significant risk to the transplant 
recipient. In autopsy series, ovaries contained metastasis in 25-50% of 
neuroblastoma cases (Oktay, 2001). Shaw et al. has reported that small pieces 
(around 1mm³) of fresh and frozen ovarian grafts from AKR mice can transfer 
lymphoma to recipient animals (Shaw et al., 1996). However, the risk of 
transferring cancer cells depends on the disease type, activity, and stage. In 
another study (Kim et al., 1999), human frozen-thawed ovarian tissue from 
patients with Hodgkin's disease (n = 5), non-Hohgkin’s lymphoma (NHL) (n = 13), 
acute lymphoblastic lymphoma (n = 2), and acute myelocytic leukemia (n = 2) 
were xenografted into immunodeficient mice. Although none of the tissues from 
patients with NHL resulted in cancer recurrence, one xenograft from a patient with 
Hodgkin's disease resulted in recurrence (one out of five). The results with tissues 
from patients who had acute myelocytic leukemia and acute lymphoblastic 
lymphoma were inconclusive. A study using a NUDE/SCID xenograft model tested 
the safety of cryopreserved human ovarian tissue from cancer patients, and 
although this study suggested that ovarian tissue transplantation in Hodgkin’s 
disease patients was safe, it did not exclude the risk of cancer transmission in 
other types of cancer (especially hematogenous or systemic neoplasm). Breast 
cancer carries a low to intermediate risk of ovarian involvement. In the absence of 
clinical and radiological evidence of distant metastasis, ovarian involvement has 
been reported in 2-11% of cases. In most cases, a thorough clinical and 
radiological evaluation rules out ovarian involvement. Ovarian involvement in 
Wilm's tumour, lymphomas (with the exception of Burkett’s lymphoma), 
osteosarcomas, Ewing's sarcoma, and extragenital rhabdomyosarcomas is 
extremely rare. Likewise, in squamous cell cervical cancer, ovarian involvement is 
below 0.2%, including in the most advanced stages (Oktay, 2001). In order to 
further minimize the risk of cryopreserving ovarian tissue with metastasis, it is 
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necessary to develop screening methods to detect minimal residual disease 
(MRD) in ovarian tissue to eliminate the risk of cancer cell transmission with 
transplantation. Attempts to confirm the safety of ovarian tissue based on the 
absence of malignant cells by light microscopy may not be sufficient. Currently, 
molecular genetic techniques such as nested polymerase chain reaction (PCR), 
flow cytometry, fluorescence in situ hybridization (FISH), and cytogenetics have 
been applied to detect MRD before autologous peripheral stem cell or bone 
marrow transplant. The detection of specific gene translocation and 
immunoglobulin gene rearrangement in leukemia has been successful using PCR 
amplification. MRD in B cell lymphoma can be detected by a PCR-mediated 
RNase protection assay (Poiret et al., 2002). A consultation with the patient's 
medical oncologist and the oncologist's approval are required (Oktay, 2001). 
5.2.Xenotransplantation 
More controversially, immunodeficient animals could be used to grow the follicles 
to produce oocytes approaching ripeness. The growth and maturation of 
cryopreserved human primordial and primary follicles have been achieved by this 
method. However, the best site for ovarian tissue transplantation, capable of 
revascularization and providing easy access to mature follicles, has not yet been 
determined. The kidney capsule of SCID mice serves as a site for the 
transplantation of ovarian slices from various species. Sheep and cat ovarian 
cortical slices were transplanted to this site and developed to late antral stages. 
Candy et al. demonstrated that freezing and thawing do not substantially damage 
marmoset ovarian tissue, and that the cryopreserved tissue retains its ability to 
support the development of follicles at all stages of folliculogenesis, including large 
antral follicles, 21-32 weeks after transplantation (Donnez et al., 2000). Xenografts 
of ovarian tissue implanted under the renal capsule of immunodeficient mice have 
demonstrated viability of the human and monkey ovarian tissue. By studying the 
rate of fibrosis in fresh and frozen-thawed cortical slices xenografted into 
NUDE/SCID mice, an average of 40% of the graft was found to be fibrotic after 24 
days. The authors observed a significantly higher fibrosis relative to surface area 
(68%) in frozen-thawed xenografted tissue, regardless of the site of transplantation 
(either subcutaneous or intraperitoneal) (Donnez et al., 2000). 
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In a preliminary study, when freshly dissected fragments from human fetuses, 16 
gestational weeks of age, were transplanted under the kidney capsule of 
immunodeficient mice, germ cells in mitosis and at all stages of meiotic prophase 
were abundant, and initial follicular formation was observed 6 months after grafting 
In addition, a pilot report showed development of antral and secondary follicles 6 
months after transplantation in a FSH-treated host grafted with PROH frozen-
thawed ovaries from a human fetus 21 gestational weeks of age. Transplantation 
of fresh or frozen-thawed human ovarian fragments from women under the kidney 
capsule of immunodeficient mice has also been described. Antral development 
was achieved in grafts from fresh and PROH frozen-thawed tissue. Four studies 
have been published on subcutaneous transplantation of fresh or frozen-thawed 
human ovaries from women. All showed active angiogenesis in the grafts and 
follicular survival. Administration of FSH to mice grafted with fresh or PROH or 
DMSO frozen-thawed tissue resulted in growth to antral stages. However, the 
grafts were reduced in size and fewer subcutaneous than kidney grafts were 
recovered. However, no differences were observed in follicular recovery, density, 
or ultrastructural quality at both grafting sites (Oktay et al., 2001). 
Neovascularization of the graft remains one of the key factors for its survival. 
Ovarian tissue is a rich source of angiogenic factors that encourage the rapid 
migration of endothelial cells into the grafts and the early restoration of blood 
circulation. The transplanted ovary is able to produce substances that promote 
direct angiogenesis, and it has been demonstrated in animal models that the 
autotransplantation of ovaries can result in prompt ovarian revascularization. 
According to Dissen et al., 1994 gonadotropin secretion after ovarian 
transplantation contributes to the revascularization of grafts in the rat by 
upregulating the gene expression of two major angiogenic factors, vascular 
endothelial growth factor (VEGF) and transforming growth factor-alpha (TGF-α). 
Using a morphometric study, Nisolle et al., 2000 demonstrated a vascular network 
located at the periphery of the graft, but macroscopic and microscopic differences 
were observed according to the site of transplantation. Indeed, when ovarian 
grafts were implanted subcutaneously, the authors observed macroscopic 
differences between fresh and frozen-thawed grafts. Indeed, fresh ovarian grafts 
were systematically well revascularized and small vessels were visible on the graft 
surface after 3 weeks, confirming that small pieces of fresh ovarian tissue (2 mm) 
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rapidly become revascularized (Donnez et al., 2000). 
5.3.In vitro growth and maturation  
The risks of ovarian tissue transplantation could be eliminated by obtaining 
primordial follicles (PMFs) from frozen-thawed tissue and, growing them in vitro, 
followed by routine IVF (Donnez et al., 2000). The development of follicles in the 
ovary is a complicated event. Primordial germ cells arise at about 3 weeks after 
fertilization and migrate by amoeboid movements from the epithelium of the yolk 
sac via the connective tissue of the hindgut to the genital ridge. During their 
journey, the primordial germ cells multiply rapidly. In humans, the genital ridge is 
formed at about 3.5–4.5 weeks of gestation by a knot of mesenchyme overlaid by 
coelomic epithelium. At about week 7 of gestation, the cells derived from the 
mesonephros and the coelomic epithelium migrate inward from the genital ridge, 
forming primitive medullary cords and sex cords, respectively. The cords, which 
are anatomically less well defined in females than in males, are compacted in the 
cortical region of the primitive gonad. The primitive cords are colonized by the 
primordial germ cells. In the female fetus, the primordial germ cells are named 
oogonia upon arrival in the primitive gonad. The oogonia are still interconnected by 
cytoplasmic bridges. The primitive medullary cords degenerate to be replaced by 
highly vascularized ovarian stroma. The cord cells proliferate and mesenchymal 
cells condense around the oogonia to form the individual primordial follicles. 
Follicle formation in humans begins in the inner part of the ovary, near the rete 
ovarii, between week 16 and week 18 of fetal life. In the primordial follicles, the 
mesenchymal cells secrete an outer basement membrane and the same cells will 
give rise to granulosa cells in the growing follicle. Meanwhile, the mitotic activity of 
the oogonia ceases and the oogonia enter meiosis (Byskov, 1986). 
In mammals, this process of envelopment of oogonia occurs either before birth 
(humans, cows, and sheep) or shortly thereafter (mice, rats, and hamsters). A 
meiosis-initiating factor is derived from the cells of the ingrowing mesonephric 
tissue when the first meiotic division is initiated. Once the meiotic process is 
initiated, the oogonial germ cells are defined as primary oocytes. As a 
consequence of initiation of meiosis, multiplication is prohibited and the store of 
female gametes is set definitively at that stage of life. Once primordial follicles are 
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formed the first meiotic division is arrested at the diplotene stage. The 
chromosomes decondense and are packed within a nucleus known as the 
germinal vesicle. In humans, the follicle may remain at this stage of development 
for 40–50 years up to the moment at which a signal initiates oocyte and follicle 
growth. All remaining oogonia that are not surrounded by somatic cells are 
expelled from the ovary (Baker, 1963). Follicles develop from primordial follicular 
stage (inactive) to primary follicular stage (active) under an unknown initiation 
signal. Human primordial follicles grow from a size of 30¯60 μm to 15¯20 mm in 
preovulatory follicle as shown in figure 2 (Macklon and Fauser, 1998). 
During this process, zona pellucida develops to 20-25 μm in diameter as the 
oocyte matures. Granulosa cells proliferate and become steroidogenic. A fluid-
filled antrum forms between granulosa layers. The surrounding stromal cells 
transform to theca interna and externa outside the basal lamina of follicles (Qu et 
al., 2000). The maximum number of germ cells is present at about 4–5 months 
after conception, and decreases from 8 × 106 to 1–2 × 106 at birth by a process 
called ´attrition` (Baker, 1963). During prepubertal life continuous initiation of 
follicle growth leads to further depletion of the store of gametes available. There 
are few reports on the number of primordial follicles in fetuses. The data from 
(Baker, 1963) and (Sforza et al., 1993) indicate that there is a trend towards 
increasing numbers of primordial follicles with gestational age. The limited data on 
early follicle growth stages in human fetal ovaries show that at birth in humans < 
1% of follicles have developed further than the primary stage. Antral follicle stages 
can be observed in human fetal ovaries (Fig. 3) (Smitz and Cortvrindt, 2002). 
The earliest stages of ovarian folliculogenesis are morphologically similar in 
different mammalian species. However, each species has its own specific 
timescale for development. In rodents (mice, rats) the time span between initiation 
of follicle growth and formation of the antral cavity is a few weeks; in large 
domestic animals it takes several months. During the preantral growth phase, the 
oocyte grows rapidly and reaches almost its maximum volume when the first 
accumulation of fluid is observed within the granulosa. In humans, Gougeon 
(1986) estimated that the maturation phase from primordial to primary follicle takes 
> 120 days as shown in figure 4 (Smitz and Cortvrindt, 2002). Once in the growing 
pool, the follicle requires 65 days to reach the early antral phase (follicle of 2–5 
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mm diameter), at which point it becomes dependent on gonadotrophins for further 
growth. Eppig and O’Brien were the first to report the development of primordial 
oocytes from newborn mouse ovaries to mature oocytes in vitro. The transfer of 
two-cell-stage embryos resulted in live birth of a mature pup. In this study a two-
step strategy was developed: first, the whole ovaries of newborn mice were 
cultured for 8 days to allow the development of secondary follicles within the 
ovarian tissue. The second step was to enzymatically isolate the oocyte-granulosa 
cell complexes and culture them for an additional 14 days. This basic two-step 
strategy will probably serve as the essential framework for application to other 
species, for several reasons: 
First: it is difficult to isolate and culture intact primordial folicles. 
Second: the mechanism involved in the recruitment of PMFs into the pool of 
preantral follicles is unknown and may require the presence of ovarian factors 
external to the follicle itself. 
Third: properly timed isolation and culture of oocyte-granulosa cell complexes 
probably enhances the development and nutrition of larger antral follicles. 
Alternatively, final oocyte maturation could be achieved by a combination of in vivo 
transplantation of PMFs, followed by in vitro culture of growing follicles (Liu et al., 
2000). Although the culture of ovarian follicles to various stages of maturity is well 
established in species such as mice, rats, sheep, and cows, growth of human 
follicles has met with limited success (Hardy et al., 2002). Techniques to grow 
human follicles in vitro are currently being developed and have been, in general, 
adapted from those used successfully in other species. Preantral follicles have 
been isolated enzymatically and mechanically and grown for several weeks, and 
some follicles have undergone antrum formation. Long-term culture of primordial 
follicles from fetal ovaries has resulted in follicle growth, oocyte maturation and 
even first polar body expulsion. In contrast, PMFs isolated from adult ovaries 
initiated growth, but did not survive beyond 24 h in vitro, and sustained high rate of 
oocyte loss (Hardy et al., 2002). One of the most promising techniques for 
preantral follicle culture is that of the tissue-slice culture system designed for the 
growth of human primordial, primary, and secondary follicles to large preantral and 
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occasionally early antral stages. Follicles are cultured within small pieces of 
ovarian cortex, which has the advantage of maintaining all the normal ovarian 
intercellular contact and support. Most PMFs initiate growth in human ovarian 
cortex, although many follicles undergo atresia during culture. Studies using this 
approach have shown that supplementation of the culture with FSH significantly 
reduces atresia, and stimulates follicle development, demonstrating that follicles 
are responsive to FSH before antrum formation (Wright et al., 1999). However, for 
the future of the IVG and IVM in human, a three-stage system encompassing 
initiation of growth in cortex pieces, follicle isolation and further in vitro growth 
followed by oocyte retrieval and IVM is envisaged for the production of oocytes 
competent to be fertilized (Abir et al., 1999)]. 
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Fig. 2. Schematic diagram of follicular development in the human. 
Primordial follicles entering the growth phase form primary follicles (class 1). This 
is followed by gonadotropin-independent (tonic) growth (class 1-4) and eventually 
gonadotropin-dependent growth. The overall development takes three cycles. 
 
 
  
60 
Fig. 3. Overview of follicle formation and growth in the human fetal ovary. 
(a) Section through a fetal ovary at week 18 of gestation. Follicles are not yet 
organized. The large clear cells with the largest nuclei, observed mainly in the 
central portion of the section, are oogonia. (b) Part (a) at larger magnification. 
Oogonia are dispersed within mesenchymal cells. Cells from the coelomic 
epithelium form cords. At this stage oogonia are still interconnected by 
cytoplasmic bridges and appear as strings (arrow). The fetal ovary is delineated 
by coelomic epithelium. (c) Ovary from a fetus at week 24 of gestation. Oogonia 
can be observed which are entirely surrounded by pregranulosa cells and form the 
primordial follicle. The tissue already shows lytic changes. Follicles are embedded 
within mesenchymal tissue, which is highly vascularized. (d) Ovary from a fetus at 
week 25 of gestation. Follicles at the primordial stage with flattened pregranulosa 
cells are present. There is a follicle containing a growing oocyte (arrow) showing 
the cuboidal transformation of the pregranulosa cells. (e) Fetal ovary (week 30 of 
gestation) showing lytic changes. Primordial follicles are observed. In the right 
upper quadrant there is a follicle with three to four layers (arrow) surrounded by a 
theca interna containing a collapsed oocyte. (f) Fetal ovary (week 34 of gestation). 
The left half of the figure contains large (atretic) multilayered follicles, the right half 
contains very dense tissue populated with primordial follicles and oogonia. Scale 
bars represent (a) 20 mm, (b) 10 mm, (c,d) 25 mm, (e) 30 mm, (f) 150 mm. 
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Fig. 4. Earliest stages of follicle growth in humans. 
The relationship between follicle diameter (x-axis) and oocyte diameter (y-axis) is 
shown and major milestones in follicle formation and differentiation are indicated. 
AR: androgen receptor; ER: oestrogen receptor; FSHr: FSH receptor; GC: 
granulosa cells; LHr: LH receptor; TC: theca cells. 
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6. Growth factors and OTCP 
Qu et al., 2000, found that transforming growth factor-alpha (TGF-α), epidermal 
growth factor (EGF) and EGF receptors were expressed in human follicles and this 
leads to the assumption that TGF-α or EGF may be useful to add to the culture of 
cryopreserved ovarian tissue to promote the maturation of follicles in vitro. The 
possible influence of freezing and thawing on the immunoreactivities of TGF-α, 
EGF and EGF receptor in frozen ovarian tissue was investigated. The authors 
observed that there was no significant difference in immunostaining for TGF-α, 
EGF and EGF receptor between fresh and frozen ovarian tissues, indicating that 
human ovarian tissue could be frozen without substantially altering the 
immunoreactivities of TGF-α, EGF and EGF receptor follicles. TGF-α and EGF 
receptor were simultaneously expressed in the early follicles of human ovarian 
tissue. TGF-α might play a role in the regulation of folliculogenesis through binding 
to EGF receptor by an autocrine or paracrine mechanism. EGF was expressed in 
a different pattern from TGF-α and EGF receptor in follicles. These growth factors 
may be useful to promote the in-vitro maturation of follicles from cryopreserved 
ovarian tissue, for potential uses in the treatment of infertile patients and in in-vitro 
fertilization programmes in the future (Qu et al., 2000). Like insulin-like growth 
factor (IGF), TGF-β is an important intra-ovarian regulator of folliculogenesis. TGF-
β was localized immunocytochemically in ovarian granulosa and theca-interstitial 
cells. The dominant form present in granulosa cells is TGF-β. Both theca-
interstitial and granulosa cells secreted TGF-β in culture. An increase in TGF-β 
levels was recently observed in ovarian follicular fluid in women after ovarian 
hyperstimulation for IVF. TGF-β differentially regulated DNA synthesis and the 
proliferation of granulosa cells, and induced apoptosis in rat theca-interstitial cells. 
TGF-β enhanced basal and gonadotropin-stimulated steroidogenesis in granulosa 
and thecal cells although both inhibin and TGF-β suppressed luteinizing hormone-
induced oocyte maturation in preovulatory follicles (Donnez et al., 2000). 
In another study, Qu et al. observed that the expression of TGF-β type II receptor 
was distinct from the type I receptor with respect to cellular distribution in ovarian 
tissue. TGF-β type II receptor stained only in the oocytes of primordial and primary 
follicles, faintly in the thecal cells, and no significant staining occurred in the 
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oocytes and granulosa cells in preantral and antral follicles. Their results are not 
consistent with the report by Roy and Kole on the expression of TGF-β type II 
receptor in granulosa, thecal and interstitial cells in the ovary. The reason for the 
discrepancy is unknown. The significance of the concomitant presence of TGF-β 
receptors and IGF type I receptor in early follicles has yet to be illuminated. 
However, it has been suggested that both IGF-I and TGF-β may be involved in a 
sophisticated paracrine-autocrine network in the regulation of oocyte maturation 
and follicular growth in the ovary, and it could be worthwhile to investigate further 
the possibility of using IGF-1 and TGF-β to regulate the in vitro or in vivo growth of 
oocytes in early follicles from cryopreserved ovarian tissue (Donnez et al., 2000). 
Results from Qu et al. showed that there was no significant difference in 
immunostaining for either IGF type I receptor or TGF-β type I and II receptors in 
follicles of frozen ovarian tissues, compared with fresh tissues from pair-controlled 
samples. It seems that freezing does not significantly alter the immunoreactivities 
of IGF type I receptor and TGF-β type I and II receptors in follicles after ovarian 
tissue cryopreservation (Donnez et al., 2000). 
 
7. Evaluation of the viability of the cryopreserved ovarian tissues. 
There are many ways to examine the viability of the cryopreserved ovarian tissue. 
7.1. Histological evaluation 
Using the light microscope, different scoring systems were proposed to evaluate 
the structural normality of the cryopreserved ovarian follicles. Paynter’s et al. 
proposed the following scoring system (paynter et al., 1999):  
Primary follicles (small follicles containing a germinal vesicle-stage oocyte 
surrounded by 1-2 layers of cuboidal granulosa cells) were graded 1-3: 
Grade 1: being spherical in shape with even distribution of granulosa cells, intact 
theca and a spherical oocyte. 
Grade 2: having theca and granulosa cells pulled away from the edge of the follicle 
but the oocyte still spherical. 
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Grade 3: having theca and granulosa cells pulled away from the edge of the follicle 
with severe pyknotic nuclei in the granulosa cells and oocyte mis-shapen 
with/without vacuolation. 
Pre-antral follicles (larger follicles surrounded by several layers of granulosa cells 
and containing a germinal vesicle-stage oocyte) were also graded 1-3: 
Grade 1: is an intact spherical follicle with evenly distributed granulosa and theca 
cells, small spaces between cells being acceptable with a normal spherical oocyte. 
Grade 2: is an intact spherical follicle with intact theca cells but with disruption of 
the granulosa cells and apparent loss of cells and containing a normal spherical 
oocyte. 
Grade 3: shows great disruption and loss of granulosa cells with theca cells pulled 
away from the follicle edge with many pyknotic nuclei visible and mis-shapen 
vacuolated oocyte. 
Using the electron microscope, the ultrastrucural changes can be evaluated by 
examining the different organelles as the microvilli, mitochondria, cortical granules 
vesicles and zona pellucida (Fuku et al., 1995). 
7.2. Endocrinological evaluation 
Follow up of the endocrine functions in animals transplanted with the 
cryopreserved ovarian tissue can give an idea about the viability of the 
cryopreserved ovarian tissues. Sugimoto et al., transplanted vitrified-thawed left 
ovarian tissue, under the right renal capsule of 10-12-days-old rats and in the 
same sitting the right ovary was completely removed. Vaginal opening is checked 
daily on postnatal day 26, and after that until postnatal day 84. Vaginal smears 
were examined daily by light microscopic observation of Giemsa-stained smears 
to detect the phase of estrous cycle (Sugimoto et al., 2000). Direct measurement 
of the gonadotrophin level or steroid hormone level in the sera of the transplanted 
animals or human is a direct way to evaluate the graft viability. Bedaiwy et al. 
measured the level of serum estradiol and follicle stimulating hormone after 
heterotopic transplantation of the ovarian tissue in ewes (Bedaiwy et al., 2003). 
Callejo et al. evaluated estradiol and follicle stimulating hormone levels in 4 
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premenopausal patients after heterotopic ovarian transplantation (Callejo et al., 
2001). 
7.3. Auto-radiographic and in situ methods for detecting apoptotic DNA 
fragments. 
These methods depend upon the fact that apoptosis is associated with activation 
of the calcium/magnesium-dependent endonuclease activity, which specifically 
cleaves cellular DNA between regularly spaced nucleosomal units. The end result 
is the generation of DNA fragments in size multiples of 185-200 base paires, which 
can be visualized as a distinct ladder of DNA bands after agarose gel 
electrophoresis and ethidium bromide staining. After extraction of DNA, terminal 
transferase is used to attach labeled dideoxy-ATP (dd-ATP) to free 3´-ends of all 
DNA fragments, followed by size fractionation using agarose gel electrophoresis. 
The qualitative aspect of DNA degradation is revealed by autoradiography, 
whereas the quantitative estimation of apoptosis is determined by β-counting of 
gel fragments containing low molecular weight DNA (<15 kilo-bases) (Aaron et al., 
1994). Cell death can be identified by TUNEL analysis as well. A kit designed for 
this purpose is used. Briefly, the tissues to be examined for apoptosis are 
immersefixed in 4% paraformaldehyde, processed for routine paraffin histology, 
sections (5 um) were deparaffinized, pretreated with proteinase K (20 ug/mL), 
quenched with 3% hydrogen peroxide, and the TUNEL procedure conducted 
according to the manufacturer’s instructions. TUNEL-positive cells were visualized 
with diaminobenzidine and counterstained with methyl green (Brendan et al., 
2000). 
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M A T E R I A L S  A N D  M E T H O D S  
1. Animals 
Twelve- to twenty-week-old OF1 female mice were used in this study, and housed 
in the animal house (Geneva University). All mice were housed under a 12-h 
light/12-h dark regime at 22-24°C with food and water supplied ad libitum. The 
animals were classified into two groups, the vitrification and the control groups. 
2. Tissue collection and transplantation 
The mice were anaesthetized by intra-peritoneal injection of Ketarom in a dose of 
0.01mL/gm/body weight (Ketarom is prepared by adding 2.4 mL of ketamine 
hydrochloride and 0.8mL of rumpun to 6.8mL of normal saline and kept at +4°C). 
Laparotomy was done through a midline or transverse incision in the ventral 
aspect of the mouse. 
In the vitrification group, the operative technique was done in two settings at two 
weeks interval. 
In the first setting, the left ovary was excised, cut into nearly 4 equal pieces by 
sterile and sharp knife, subjected to the vitrification technique as will be 
mentioned, and the left ovarian pedicle was ligated with vicryl 4/0 to ensure 
hemostasis. Continuous sutures closed the peritoneum while Interrupted sutures 
using either nylon 6/0 or vicryl 4/0 closed the skin. 
In the second setting, another laparotomy was done two weeks later to remove the 
right ovary and to transplant one cryopreserved left ovarian quarter in the cavity of 
the most distal part of the left uterine horn. 
In the control group, the operative technique was done in only one setting. 
Laparotomy was done as described before, both ovaries were removed, both 
ovarian pedicles were ligated with vicryl 4/0, and the left ovary was cut into nearly 
4 equal pieces by sterile and sharp knife. One ovarian quarter was washed in HB1 
solution and then immediately transplanted in the cavity of the most distal part of 
the left uterine horn. 
3. Vitrification of the ovarian tissue 
The vitrification solution (VS) is prepared by adding to HB1 solution the following 
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cryoprotectants to form 100% concentration of VS: 
Dimethyl sulphoxide (DMSO): 20.5% V/V, acetamide: 15.5% W/V, propylene 
glycol: 10.0% V/V, and polyethylene glycol 6000 (average molecular weight 7500): 
6.0% W/V. 
HB1 solution consists of a modified Dulbecco’s saline solution containing: 
phosphate buffer: 1mM, sodium pyruvate: 0.33 mM, glucose: 5.56 mM, bovine 
serum albumin: 300 mg, and penicillin G: 100 IU/mL. 
Dilution of 100% concentration of VS with HB1 solution allows the formation of 
12.5%, 25%, and 50% concentrations of VS. 
The ovaries were collected, cut into nearly 4 equal pieces by sterile and sharp 
knife, washed in HB1 solution and then exposed successively to an ascending 
concentration of the croprotectant. Firstly at room temperature, the ovarian 
fragments were exposed to 12.5% VS for 15 min, then to 25% VS for another 15 
min to allow the tissues to be completely infiltrated by the cryoprotectants. 
The ovarian suspension was then transferred to a cold room (at +4°C) where the 
ovarian fragments were exposed to 50% VS for 15 min. and then finally to 100% 
VS for another 15 min. then each ovarian fragment was placed in a freezing tube 
with 0.5 mL 100% VS, then transferred to the liquid nitrogen, and preserved until 
used. 
4. Thawing 
The ovarian suspension was re-warmed by putting the freezing tubes for few 
seconds in water warmed to 37°C. The remaining cryoprotectants were then 
washed away by passing the ovarian fragments in a descending concentration of 
the cryoprotectant as soon as the samples were liquified, firstly in 50% VS, 
secondly in 25% VS, thirdly in 12.5% VS, and lastly the ovarian peices were put in 
HB1 solution. 
5. Assessment of the ovarian tissue viability and functionality 
5.1.Viability of the ovarian biopsies 
Viability of the previously vitrified-thawed ovarian fragments and that of the control 
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group was assessed by histological examination of the ovarian fragments before 
and after intrauterine transplantation. The ovarian biopsies and grafts were 
collected, fixed in acetic formol solution and embedded in paraffin. Serial sections 
(5 um) were cut, stained with hematoxylin and eosin, and examined under light 
microscope. Viable and atretic follicles were assessed according to Braw and 
Tsafriri criteria (Braw and Tsafriri, 1980): 
Non-atretic follicles: contain oocytes in the resting stage of prophase, and pyknotic 
nuclei in the granulosa cell layer are absent. Follicular fluid is clear, i.e. without cell 
debris or macrophages. The theca interna consists of a few layers of elongated 
cells. 
Stage 1 atresia: the oocytes of these follicles are in the resting stage of prophase 
and 1-10% of the nuclei in the granulosa cell layer are pyknotic. Mitotic figures are 
seen. The follicular fluid contains some cell debris.  
Stage II atresia: in most of the follicles meiosis-like changes such as 
chromosomes at metaphase or a polar body could be observed. In the granulosa 
layer 10-30% of the nuclei are pyknotic, and mitotic figures could also be seen. 
Follicular fluid contains much cell debris. 
Stage III atresia: the oocyte is fragmented or pseudocleaved. Most of the 
granulosa cells disappeared and macrophages are seen in the follicular fluid. The 
theca interna cells are hypertrophied. As atresia progresses the follicles collapse. 
5.2.Functionality of the transplanted ovarian biopsies 
Functionality of the transplanted ovarian biopsies was evaluated by restoration of 
fertility in the grafted animals. One month afer transplantation, the grafted animals 
were stimulated by PMSG in a dose of 10 IU followed 48 hours later by hCG 
injection in a dose of 5 IU and mating was allowed with previously known fertile 
males. Successful mating was checked by the presence of vaginal plug. Fecundity 
of the ovarian grafts was calculated and expressed as the total number of live 
pups/ total number of the grafted ovarian tissues. 
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6. Statistical analysis 
The unpaired t-test was used to analyse the numbers of viable follicles in fresh 
and vitrified-thawed biopsies as well as in fresh and vitrified-thawed grafts. The 
descriptive data were presented as mean ± SD. Differences at a probability of p≤ 
0.05 were considered significant. 
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R E S U L T S  
1. Viability of the ovarian follicles after thawing 
Samples of fresh ovarian tissue were fixed within 30 minutes of collection to 
compare with vitrified-thawed ovarian tissue fixed immediately after thawing. 
Freshly excised ovarian tissue showed the presence of primordial, to cavitary 
follicles as well as corpus luteum (Figure 5). The vitrified–thawed ovarian tissue 
showed also primordial, primary, pre-antral follicles and corpora lutea (Figure 6). 
The nuclei and cytoplasm are unaltered by freezing at -196°C. Table 12 shows the 
mean number of morphologically normal follicles present in pieces of fresh (n = 7) 
and vitrified-thawed (n = 7) ovarian biopsies. The mean number of primordial, 
primary, pre-antral and antral follicles in the control group was significantly higher 
than those observed in the vitrified-thawed ovarian biopsies. 
 
Table 12: Comparison of follicle number in fresh and vitrified-thawed ovarian 
biopsies. 
 
Ovarian biopsy Primordial 
follicles 
Primary 
follicles 
Pre-antral 
follicles 
Antral 
follicles 
Fresh biopsy 
(n = 7) 
389 ± 55.6 80 ± 17 41 ± 8.3 7 ± 1.9 
Vitrified-thawed 
biopsy (n = 7) 
 
294 ± 44.9* 53 ± 7.5† 25 ± 2.6‡ 3 ± 1.6§ 
P value * = 0.0040, P value † = 0.0025, P value ‡ = 0.0005, and P value § = 
0.0017 
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Figure 5: Light micrograph of fresh ovarian biopsy 
a. Fresh ovarian biopsy had primary follicle (notched arrow), mid-antral follicle 
(green arrow head), and corpus luteum (black arrow head) (magnification, X50). 
b. Higher magnification of fresh ovarian biopsy showing primordial follicle (notched 
arrow), primary follicle (black arrow head), and pre-antral follicle (green arrow 
head) with visible oocytes (magnification, X200) 
 
 
 
 
 
a b 
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Figure 6: Light micrograph of vitrified/thawed ovarian biopsy 
a. Vitrified-thawed ovarian biopsy showing primordial follicle (green arrow head) 
and primary follicle (black arrow head) (magnification, X50). 
b. Higher magnification of Vitrified-thawed ovarian biopsy showing primordial 
follicle (green arrow head), and primary follicle (black arrow head) with visible 
oocytes (magnification, X200) 
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2. Viability of the ovarian follicles after grafting 
The ovarian grafts were retrieved from 3 control and 4 test mice one month after 
grafting. Histological examination showed that transplanted grafts in both the fresh 
and frozen groups contained follicles at all stages of folliculogenesis and corpora 
lutea (Figure 7). Table 13 showed a comparison between the follicle number in-4-
week-old grafts after transplantation of fresh and vitrified-thawed ovarian biopsies. 
The mean number of different types of follicles in both fresh and vitrified-thawed 
grafts was not significantly different (P value = 0.6) 
 
Table 13: Comparison of follicle number in-4-week-old grafts after 
transplantation of fresh and vitrified-thawed ovarian biopsies 
 
Ovarian grafts Primordial 
follicles 
Primary 
follicles 
Pre-antral 
follicles 
Antral 
follicles 
Fresh grafts 
(n = 3) 
197 ± 18.7 77 ± 8.1 42 ± 7.7 7 ± 1 
Vitrified-thawed 
grafts (n = 4) 
 
212 ± 44.3 69 ± 
13.4 
45 ± 7.3 6 ± 1.7 
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Figure 7: Transplantation success of ovarian biopsies in the uterine cavity of 
bilaterally ovariectomized mice. 
a. Fresh ovarian transplant had primary follicle (notched arrow), early antral follicle 
(green arrow head), mid antral follicle (black arrow head), and corpus luteum 
(white arrow) (magnification, X200). 
b. Vitrified-thawed ovarian transplant had primordial follicle (notched arrow), 
preantral follicle (white arrow), early antral follicle (green arrow head), and mid 
antral follicle (black arrow head) (magnification, X200) 
 
 
 
 
a b 
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3. Restoration of fertility 
The functionality of the transplanted ovarian grafts was evaluated by restoration of 
fertility in the transplanted animals. One month after transplantation, PMSG was 
injected followed by hCG and mating was allowed at the expected time of 
ovulation with previously known fertile males. Fecundity of the ovarian grafts was 
expressed as the total number of live pups/ total number of the grafted ovarian 
tissues. The values were 0.2 and 0.42 for the cryopreserved and fresh ovarian 
grafts respectively. A similar number of fertile recipients of fresh and frozen grafts 
had obtained as shown in table 14. However, the number of pups obtained from 
fresh graft recipient was significantly different from that of the recipients of vitrified-
thawed grafts. Interestingly, the mice carrying fresh grafts gave birth to 7 viable 
pups and one stillbirth. After 12 weeks, the fertility of the living pups was confirmed 
by producing second generation of mice on natural mating, demonstrating that 
these mice were anatomically normal in terms of fertility. While the recipients of 
vitrified-thawed grafts gave birth to 2 fresh stillbirths and 2 neonatal deaths. 
Autopsy of the 2 fresh stillbirths revealed unilateral pulmonary hypoplasia in both 
of them (Figure 9), while the autopsy of the 2 neonatal deaths revealed no 
abnormality. 
Table 14: Evolution and outcome of pregnancies in mice after ovarian tissue 
transplantation 
 
Ovarian 
graft 
Number of 
females 
transplanted 
Number of 
fertile 
females 
Number of 
pups/pregnancy 
Outcome of  
deliveries 
Fresh 
graft 
19 2 4 7 viable and fertile 
1 Neonatal death 
 
Vitrified-
thawed 
graft 
20 2 2 2.Fresh stillbirth 
2.Neonatal death 
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Fig. 8 Autopsy picture and light micrograph of the lung of mouse pup with 
unilateral pulmonary hypoplasia 
a. Mouse stilbirth showing normal development of all body systems namely the 
central nervous system, the heart, the urinary system, and the gastro-intestinal 
system, which are coincident with full term mouse. However one lung appears 
smaller than the other and collapsed, which means the presence of unilateral 
pulmonary hypoplasia. 
b. Histological examination of the collapsed lung, revealed deficient septation and 
thick-walled mesenchyme (arrows) a findings coincident with lung hypoplasia 
together with large amounts of transudate filling both lungs (black arrow heads) 
which means that it was borne dead and never breath before (magnification, 
X200). 
 
a 
b 
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D I S C U S S I O N  
Assessment of various ovarian functions after transplantation is a direct way to 
examine viability of the preserved ovarian tissue. In many previous studies, 
viability of the cryopreserved ovaries and ovarian tissue was assessed by 
functional or morphological analysis after transplantation into orthotopic (Gosden 
et al, 1994; Cox et al., 1996; Harp et al., 1994; Aubard et al., 1998) or heterotopic 
sites (Nugent et al., 1998; Schnorr et al., 2000; Newton et al., 1996). In this study, 
survival of the cryopreserved ovarian tissues was assessed by histological 
examination and restoration of fertility in the grafted mice after natural mating and 
we have shown that ovarian tissue from mice containing follicles at different stages 
of development can be cryopreserved and is capable of surviving freezing and 
thawing. This is the first study that showed that this cryopreserved ovarian tissue 
could restore fertility to ovariectomised mice after heterotopic transplantation and 
natural mating without the need for medical assistance. 
In this study, we found a statistically significant difference between the fresh and 
cryopreserved biopsies regarding all types of ovarian follicles. This is in agreement 
with Migishima et al. 2003 that showed significant difference between fresh and 
vitrified–thawed ovaries (Migishima et al., 2003). Jeremias et al. 2003 indicated 
that the number of primordial follicles per high power field was significantly 
reduced in the cryopreserved samples as compared to the freshly fixed group 
while changes in the percentage of primary and secondary follicles were not 
statistically significant (Jeremias et al., 2003). Our findings are not in agreement 
with Salle et al. 1999 that concluded that histological analysis of the fresh ovarian 
fragments showed primordial to cavitary follicles. Freezing and thawing of the 
ovarian fragments did not damage the ovarian structure and the number and 
distribution of follicles were identical to those in the fresh control sample (Salle et 
al., 1999). Fabbri et al. 2003 found statistical insignificant difference between the 
fresh and frozen/thawed ovarian tissue regarding the follicle morphology, the 
follicular density, the follicular distribution and the mean follicle diameter (Fabbri et 
al., 2003). Hovatta et al. 1996 indicated in a comparative study of fresh and 
frozen/thawed ovarian tissue using DMSO or PROH as cryopretectants, that there 
was no essential difference in the morphological appearance before and after 
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freezing and thawing (Hovatta et al., 1996). Paynter et al. 1999, also showed 
insignificant difference between different types of follicles in the fresh and 
cryopreserved ovarian biopsies using the slow cooling technique (Paynter et al., 
1999). Candy et al. 1995 showed that freezing and thawing don’t substantially 
damage marmoset ovarian tissues and that the cryopreserved tissues retain its 
ability to support the development of large antral follicles after transfer beneath the 
kidney capsule of immunodificient mice (Candy et al., 1995). 
In this study, the significant reduction in the number of different types of follicles 
could be due to inadequate penetration of the cryoprotectants especially in the 
cells at the center of the tissues. Could also be due to the toxic cellular effect of 
the cryoprotectants. This cellular toxicity of the cryoprotectants can vary from non-
specific impairment of cellular components (e.g., disruption of membranes, 
denaturation of proteins) to a specific action on distinct enzymes. 
On the electron microscopic level, after vitrification and thawing of ovaries, 
Salehnia et al. 2002 concluded that, no noticeable changes occurred in the 
organelles of oocytes and follicular cells and the integrity of subcellular structure 
was well preserved (Salehnia et al., 2002). The same results were confirmed by 
Oktay et al. 200 when they showed that most cells lacked ultra-structural signs of 
damage but after cryopreservation by slow cooling technique (Oktay et al., 2001). 
Gook et al. 1999 showed that reasonable survival of both pregranulosa cells and 
oocytes can be achieved with the slow cooling procedure (Gook et al., 1999), 
while Nisolle et al. 2000 reported that ovarian tissue cryopreserved by slow cooling 
showed follicles that seemed to be degenerating and that these signs are more 
frequent in secondary follicles than in primordial follicles (Nisolle et al., 2000). 
In this study, we have shown also an insignificant difference between the number 
of different types of ovarian follicles in the cryopreserved and fresh grafts. This 
was in agreement with Kagabu and Umezu 2000 who evaluated by histological 
examination the effects of vitrification, thawing and transplantation on the ovarian 
tissues from mouse, Chinese hamster, rabbit, Japanese monkey and rat and 
concluded that their results suggest that vitrification, thawing and transplantation 
do not greatly damage the ovarian tissue (Kagabu and Umezu, 2000). Candy et al. 
1995 also showed no difference between grafts of fresh and cryopreserved 
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ovaries by slow freezing (Candy et al., 1995). Wang et al. 2002 indicated that 
there was no statistical significant difference between the grafts in the control and 
cryopreserved groups, with respect to the follicle number (Wang et al., 2002). 
Our findings were not in agreement with Nisolle et al. 2000 who showed that the 
follicular density was significantly lower in transplanted cryopreserved ovarian 
grafts than in the fresh ovarian grafts (Nisolle et al., 2000). Salle et al. 1999 
indicated that the frozen/thawed autografts contained cavitary and numerous 
primordial, primary and secondary follicles. However, the number of primordial 
follicles was greatly diminished compared with the fresh control sections (Salle et 
al., 1999). 
Neovascularization of the graft remains one of the key factors for its survival. 
Ovarian tissue is a rich source of angiogenic factors that encourage rapid 
migration of endothelial cells into the grafts and early restoration of blood 
circulation. The stress of cryopreservation may stimulate the vitrified-thawed 
ovarian tissue to produce high levels of the angiogenic growth factors allowing 
rapid revascularization of the cryopreserved grafts and minimizing as much as 
possible the ischemic injury. Qu et al 2000 investigated the possible influence of 
freezing and thawing on the immunoreactivities of TGF-α, EGF and EGF receptor 
in frozen ovarian tissue and the authors observed that there was no significant 
difference in immunostaining for TGF-α, EGF and EGF receptor between fresh 
and frozen ovarian tissues, indicating that human ovarian tissue could be frozen 
without substantially altering the immunoreactivities of TGF-α, EGF and EGF 
receptor in the follicles (Qu et al., 2000). However, further investigations are thus 
needed in order to evaluate the influence of cryopreservation, thawing, and 
transplantation on the angiogenic growth factors. Equally important, is to evaluate 
the influence of the angiogenic growth factors on the viability of the transplanted 
ovarian tissue. 
The idea of intra-uterine implantation of the ovarian tissue is not a new one, it 
dates back to year 1895. Estes operation was employed quite widely during the 
first half of this century. This operation consists of bilateral salpingectomy and 
unilateral oophorectomy followed by implantation of the cut surface of the 
remaining ovary (still attached to its pedicle) into the resected stump of one 
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oviduct and portion of the uterine horn. In 1961, Ikle reported 29 pregnancies out 
of 270 patients underwent Estes operation for tubal problems (Adams, 1979). In 
the rabbit, fertilization in utero is possible, as demonstrated by Chang (1955), 
Bedford (1969), Adams (1970) and Glass (1972). Chang transferred 26 freshly 
ovulated eggs to the uterus of a mated doe; at recovery 6 hours later, the eggs 
were found fertilized but some shows signs of degeneration. A finding which the 
other investigators has each confirmed (Adams, 1979). An orthotopic autograft of 
the ovarian biopsy may allow spontaneous pregnancy while heterotopic autograft 
can restore ovarian secretion, however, medical assistance would be necessary to 
obtain a pregnancy (Salle et al., 1998). In this study we have shown for the first 
time that heterotopic autograft of cryopreserved as well as fresh ovarian tissue 
without vascular pedicle can lead to spontaneous pregnancy without medical 
assistance. Fecundity of the ovarian grafts was expressed as the total number of 
live pups/ total number of the grafted ovarian tissues. The values were 0.2 and 
0.42 for the cryopreserved and fresh ovarian grafts respectively. Despite the 
partial reduction in fecundity, the present results indicate that the fresh as well as 
cryopreserved/thawed ovarian tissues were functional and fertile after heterotopic 
transplantation into the recipients. This reduction in fecundity may be due to 
expulsion of the ova from the uterus soon after ovulation as stated by Estes and 
Heitmeyer (Adams, 1979). In the present study, we tried to investigate the possible 
cause of low fecundity, so, 5 grafted uterine horns, were excised from mice in 
which pregnancy have failed to occur. Histological examination revealed 
disappearence of the graft from one uterine horn. This is in agreement with Candy 
et al. 1995 who recovered only 10 grafts out of 13 in the first series and 4 grafts 
out of 6 at autopsy in the second series (Candy et al., 1995). Newton et al. 1996 
also identified and recovered 100 out of 102 grafts from the original graft sites 
(Newton et al., 1996). The grafts were covered by endometrium in 3 uterine horns. 
This layer of the endometrium acts probably as a barrier, thus preventing the ovum 
from reaching the uterine cavity. This finding was also reported by Beyth and 
Polishuk, 1979 in their study to evaluate the ovarian implantation into the uterus 
(Beyth and Polishuk, 1979). Also, Salle et al. 1998 found, after orthotopic ovarian 
transplantation and failure of pregnancy, that the grafts were covered by 
peritoneum (Salle et al., 1998). In the last uterine horn, no explanation was found. 
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Ethical and legal considerations of clinical applications  
The clinical application of ovarian cryopreservation and transplantation contains 
potential legal and ethical issues, as has happened with other new reproductive 
technologies (Aubard, 2000). However, elective oophorectomy and autologous 
replacement to preserve reproductive and hormonal function in women facing 
ovarian disease or cancer appears to be an ethically acceptable procedure in 
medically appropriate cases. Its goal of enabling an otherwise infertile woman to 
produce oocytes that could lead to the birth of a healthy child is the goal 
underlying most infertility treatment. If the surgical retrieval and replacement is 
safely performed and there is a reasonable basis for concluding that the oocytes 
are healthy, there is no ethical objection to providing this procedure as a way to 
preserve fertility for medically suitable candidates (Aubard, 2000). This is the 
beginning of a new technology that has numerous unresolved ethical and legal 
issues, including clinical indications, safety, age limits, time limit for storage, and 
tissue custody. Defining clinical indications and resolving safety issues will be an 
ongoing effort, along with improvement of the technology. In addition, there is a 
high possibility of extending the application of the technology beyond the present 
indication (John and Robertson, 2000). 
The problem of informed consent leads directly to the next ethical problem. The 
child facing castration by anticancer treatment constitutes one of the best present 
indications for OTCP. But how can truly informed consent for this procedure be 
obtained from a child? How can the usefulness be weighed of a technique that she 
will only benefit from in 10 or 20 years and that will be performed by doctors who 
likely will not be the same as who extracted the tissue. Parents are often 
completely overwhelmed by the choices they have to make for their child (Aubard, 
2000). 
Is it ethical to harvest and freeze ovarian tissue without a certainty of success in 
transplantation? This technique still in a phase of clinical research and because it 
is unknown now how in the future the ovarian tissue, that was extracted from 
patients today, will be used, it is essential to very clearly inform patients of this 
situation and of the limits of the present knowledge to have a truly informed 
consent (Aubard, 2000). 
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If oophorectomy-biopsy and cryopreservation occur to preserve ovarian tissue, a 
decision will have to be made later whether to use that tissue for reproduction. In 
the case reported by Oktay and colleagues the woman who had requested 
cryopreservation had the tissue replaced in her pelvis 2 years after removal. Now 
that ovarian function has been confirmed, she may seek to have children through 
IVF of oocytes produced by the replaced ovary. If in vitro maturation of eggs 
becomes feasible, the preserved tissue could be induced to mature in vitro and 
obviate the need for autologous replacement. In either case, her eggs will have to 
be fertilized in vitro for conception to occur (John and Robertson, 2000). 
A major ethical issue would arise with this procedure if a woman requesting use of 
her preserved ovarian tissue has reached the customary age of menopause in her 
culture or has exceeded a designated age limit, e.g., 55 or 60. Perhaps the most 
important ethical factor in this situation is the health of an older woman requesting 
autologous replacement or in vitro maturation of her oocytes for the purpose of 
initiating a pregnancy in herself. She should not be free to establish a pregnancy in 
herself via these techniques unless she meets the health and responsibility criteria 
for postmenopausal pregnancy that programmes set for egg donation or other 
assisted reproductive techniques for older women. Aside from concerns of 
physical health, some people have argued against the use of medical technologies 
to extend the reproductive age of women beyond normal age of menopause on 
the ground that it is unnatural or culturally inappropriate. Such an argument is 
difficult to sustain if gender-based distinctions in access to assisted reproductive 
technologies are rejected, for some men reproduce at comparable or older ages. 
Nor would protecting the welfare of resulting children be a convincing argument 
against postmenopausal replacement or use of preserved ovarian tissue, if the 
circumstances show that the woman and her partner are likely to be responsible 
child rearers. Although reasonable people might differ on this issue, if there is 
reason to think that the woman or couple would be responsible childrearers, there 
is no compelling ethical reason beyond health to deny postmenopausal women 
this option (John and Robertson, 2000). 
Women electing ovarian preservation who face oophorectomy for cysts, 
endometriosis, or other noncancerous conditions will incur no further risk from the 
procedure, because they would in any case be undergoing an operative 
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procedure. Women facing treatment for non-ovarian cancers, on the other hand, 
would have to undergo oophorectomy prior to beginning cancer therapy, which 
could be highly burdensome for many patients. However, the risks and burdens of 
elective oophorectomy for later replacement would clearly appear to be within the 
range of risks and burdens that competent adults facing cancer therapy may 
choose to undergo. If a newly diagnosed cancer patient competently assesses the 
risks and benefits of the procedure and concludes that the benefits of preserving 
her ovarian function are worth the burdens of elective oophorectomy prior to 
cancer treatment, she and her physician should be free to elect this procedure 
(John and Robertson, 2000). 
It is unlikely that otherwise healthy women would request such a procedure. 
Elective oophorectomy would have to be performed in a woman’s 20s or early 30s 
to ensure viability of oocytes. Few healthy women in this age group are likely to 
undergo the costs and burdens of elective oophorectomy merely to hedge against 
the unknown future risk of gametic infertility. Unless they know to a high degree of 
certainty that they will not reproduce in their fertile years, the burdens of elective 
oophorectomy would seem so much greater than the benefits that a physician who 
performed an oophorectomy in this situation might well be violating the medical 
ethical principles. A dramatic reduction in the costs and burdens of ovarian 
removal might increase the demand for ovarian preservation from healthy women. 
For example, proposals to obtain ovarian tissue by biopsy followed by autologous 
replacement or in vitro maturation of follicles and oocytes might increase the 
number of women in their 20s who choose some form of ovarian preservation. 
Still, few healthy women in this age group are likely to be so concerned about their 
future infertility that they would seek a surgical intervention not covered by 
insurance merely to hedge against the possibility that they might have lost the 
ability to produce viable oocytes at a future time when they wish to reproduce. If 
ovarian biopsy proves to be a safe and effective way to obtain ovarian tissue for 
preservation, the main beneficiaries would be women facing cancer treatment, not 
healthy women generally (John and Robertson, 2000). 
Ovarian tissue could not be transplanted into other women on medical grounds, as 
it would require use of drugs such as cyclosporin to prevent rejection, increasing 
the risk of malignant disease. The use of such drugs for transplantation of organs 
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on grounds other than a threat to a person’s life was not accepted by an ethics 
committee at the Epworth Hospital, Melbourne, when tubal transplantation was 
proposed to assist in the treatment of infertility (John and Robertson, 2000). 
Finally, xenomaturation of human follicles is already possible up to antral follicles 
and it is probable that this procedure will be functional well before in vitro growth 
and maturation. However, ethical concerns raised by this technique are not at all 
trivial, because of the possibility of alterations in the human genome or the 
transmission of hitherto unknown infectious agents (Donnez et al., 2000). Although 
engaging in ovarian banking may be a personal choice of the patients who 
desperately want to preserve fertility with no other option, it is also the 
responsibility of the medical and scientific communities to prevent 
misunderstanding and misuse of this emerging technology. There are many 
reasons, after all, to proceed with care in developing this technology (Aubard, 
2000). 
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C O N C L U S I O N  
1. The ovary can tolerate exposure to osmotic dehydration and vitrification in a 
concentrated solution of cryoprotectants. 
2. Vitrification affects all types of follicles in the cryopreserved biopsies. 
3. The murine uterus is a suitable place for ovarian tissue transplantation and can 
lead to natural pregnancy. 
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